BMT CTN 0402 
A Phase III Randomized, Multic enter Trial 
Comparing Sirolimus/Ta crolimus with 
Tacrolimus/ Methotrexate as Graft -Versus -Host 
Disease (GVHD) Prophylaxis After HLA -Matched, 
Related Peripheral B lood Stem Cell 
Transplantation  
[STUDY_ID_REMOVED]  
 
 
 
A Pha
se III Randomized, Multicenter Trial Comparing  
Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as Graft-
Versus-Host Disease (GVHD) Prophylaxis After HLA-Matched, 
Related Peripheral Blood Stem Cell Transplantation 
 
 
B
MT CTN PROTOCOL 0402 
Version 4.0 
 
Stu
dy Chairpersons 
Co
rey Cutler, M.D., M.P.H., F.R.C.P.C.1 
Jo
seph H. Antin, M.D.1 
 
Pro
tocol Team   
 
James Ferrara,
 M.D.2 
Stephan Gru
pp, M.D., Ph.D.3 
Mary Hor
owitz, M.D., M.S.4 
Lau
ra Johnston, M.D.5 
Brent
 Logan, Ph.D.4 Marg
aret MacMillan, M.D.6 
Ph
ilip McCarthy, M.D.7 
Ryotaro Na
kamura, M.D.8 
David Port
er, M.D.9 
Je
nnierose D’Elia10 
 
 
Sp
onsored by [CONTACT_98376], Lung, and Blood Institute 
National Cancer Institute  
 
 
1 Dan
a Farber Cancer Institute 
2 Un
iversity of Michigan 
3 Chil
dren’s Hospi[INVESTIGATOR_6684] 
[ADDRESS_646470] University  6 Un
iversity of Minnesota 
7 Rosw
ell Park Cancer Institute 
8 City
 of Hope National Medical Center 
9 Un
iversity of Pennsylvania 
10 Th
e EMMES Corporation 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
  
Cor
e Study Participants:   Affil
iate Study
 Participants:  
City
 of Hope National Medical Center 
Dana Farber Cancer Institute 
Duke University Medical Center Ohio State University Stanford University Medical Center 
University Hospi[INVESTIGATOR_501745], San Diego University of [LOCATION_012] College of Medicine University of Michigan Medical Center University of Minnesota University of Pennsylvania Cancer Center University of Washington, Barnes Jewish Hospi[INVESTIGATOR_501746]-Louis Indiana University 
Mayo Clinic 
Roswell Park Cancer Institute [LOCATION_007] Transplant Institute Virginia Commonwealth University MCV Hospi[INVESTIGATOR_501747] & Clinics 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
i PRO
TOCOL SYNOPSIS – BMT CTN PROTOCOL 0402 
 
A
 Phase III Randomized, Multicenter Trial Comparing  
Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as Graft vs. Host Disease (GVHD) 
Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation 
 
 
Principal Investigators: Corey Cutler, M.D., M.P.H., F.R.C.P.C. 
 Joseph H. Antin, M.D.  
 Study Design:  The study is designed as a Phase III, randomized, open label, 
multicenter, prospective, comparative trial of sirolimus and 
tacrolimus versus tacrolimus and methotrexate as GVHD 
prophylaxis after HLA-matched, related peripheral blood stem cell 
transplantation in patients with hematologic malignancies.  
Recipi[INVESTIGATOR_501748]/tacrolimus or tacrolimus/methotrexate 
arms in a 1:1 ratio. 
 
Primary Objective: The primary objective is to compare the rates of 114-day Grades II-
IV acute GVHD free survival between patients in the two study arms 
from the time of randomization using an intent-to-treat analysis. 
 
Secondary Objectives:  Patients randomized to the two study arms will be compared for the 
following endpoints:  time to neutrophil and platelet engraftment, the 
incidence of Grades III-IV acute GVHD, mucositis severity, time to 
first hospi[INVESTIGATOR_501749], all infections, CMV 
reactivation and thrombotic microangiopathy incidence and VOD 
during the [ADDRESS_646471]-transplantation, malignant disease relapse 
and 1-year relapse-free and overall survival. 
 
Eligibility Criteria:  Eligible patients are between [ADDRESS_646472] acute 
leukemia, myelodysplasia, chronic myeloid leukemia, adequate 
organ function, a serologic (or higher resolution) 6/6 Class I HLA-A 
and B and molecular Class II DRB1 matched sibling donor, and are 
able to give signed informed consent prior to enrollment.   
 
Tre
atment Description: Patients will receive one of two conditioning regimens described in the protocol, at the discretion of the transplant physician.  The 
transplant physician must choose among these regimens prior to 
GVHD prophylaxis assignment by [CONTACT_17628].  Conditioning 
regimens will vary by [CONTACT_501798].  Stem 
cell donors will donate peripheral blood stem cells according to local 
institutional practices.  Peripheral blood stem cells will not be 
manipulated or T-depleted prior to administration.  Standard post-
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646473]. 
 
A
ccrual Objective:  Patients who are candidates for transplantation of G-CSF-mobilized 
peripheral blood stem cells from HLA-matched, related donors will be targeted for accrual.  Approximately 156 patients will be accrued 
per study arm (total of 312 patients). 
 Accrual Period:  The estimated accrual period is three years. 
 
Study Duration: Patients will be followed for [ADDRESS_646474] randomization for 
evaluation of the primary endpoint, with additional follow-up to two 
years after transplantation for evaluation of secondary endpoints. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
iii TRE
ATMENT SCHEMA  
 
 
 
 
 
Inf
usion of peripheral blood stem cells 
from 6/6 HLA-matched sibling donor 
Si
rolimus + Tacrolimus T
acrolimus + Methotrexate 
Rando
mization continues to 312 total subjects,  
15
6 per arm. Rando
mization Declar
e Conditioning Regimen 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
iv TABLE O
F CONTENTS 
 
 
1. BAC
KGROUND AND RATIONALE .............................................................................. 1-1  
1.1. Allogeneic Stem Cell Transplantation .............................................................................. 1-1  
1.2. GVHD Prophylaxis ........................................................................................................... 1-1  
1.3. Sirolimus ........................................................................................................................... 1-3  
1.3.1.  Preliminary Experience with Sirolimus in Stem Cell Transplantation ................................... 1-4  
[IP_ADDRESS].  Therapy of established GVHD ....................................................................................... 1-4  
[IP_ADDRESS].  Prophylaxis of GVHD .................................................................................................... 1-4  
2. STUDY DESIGN ............................................................................................................... 2-1  
2.1. Study Overview ................................................................................................................. 2-1  
2.2. Hypothesis and Study Objectives ..................................................................................... 2-1  
2.2.1.  Primary Hypothesis ............................................................................................................. 2-1  
2.2.2.  Secondary Hypotheses ........................................................................................................ 2-1  
2.2.3.  Primary Objective ............................................................................................................... 2-2  
2.2.4.  Secondary Objectives .......................................................................................................... 2-2  
2.3. Patient Eligibility for Randomization .............................................................................. 2-2  
2.3.1.  Patient Eligibility for Randomization................................................................................... 2-2  
2.3.2.  Patient Exclusion Criteria .................................................................................................... 2-4  
2.4. Conditioning ...................................................................................................................... 2-5  
2.4.1.  Additional Drugs ................................................................................................................. 2-5  
2.4.2.  Choice of Conditioning Regimen......................................................................................... 2-5  
2.4.3.  Order of Administration of TBI and Cyclophosphamide ...................................................... 2-5  
[IP_ADDRESS].  TBI administration ......................................................................................................... 2-5  
[IP_ADDRESS].  Cyclophosphamide administration.................................................................................. 2-5  
2.5. Stem Cell Transplantation ................................................................................................ 2-6  
2.5.1.  Stem Cell Collection ........................................................................................................... 2-6  
2.5.2.  Stem Cell Administration .................................................................................................... 2-6  
2.6. GVHD Prophylaxis ........................................................................................................... 2-6  
2.6.1.  Sirolimus/Tacrolimus .......................................................................................................... 2-7  
[IP_ADDRESS].  Dosing ........................................................................................................................... 2-7  
[IP_ADDRESS].  Monitoring ..................................................................................................................... 2-7  
[IP_ADDRESS].  Target serum levels and dose modifications.................................................................... 2-7  
[IP_ADDRESS].  Tapering ........................................................................................................................ 2-8  
2.6.2.  Tacrolimus/Methotrexate..................................................................................................... 2-8  
[IP_ADDRESS].  Dosing ........................................................................................................................... 2-8  
[IP_ADDRESS].  Monitoring ..................................................................................................................... 2-8  
[IP_ADDRESS].  Target serum levels and dose modification ..................................................................... 2-8  
[IP_ADDRESS].  Tapering ........................................................................................................................ 2-[ADDRESS_646475] Infections ............................................................................................ 2-9  
2.7.4.  Intravenous Immune Globulin (IVIG)................................................................................ 2-10  
2.7.5.  Kepi[INVESTIGATOR_113270] ......................................................................................................................... 2-10  
2.8. Description of Study Drugs............................................................................................. 2-10  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
v 2.8.
1. Administration and Storage ............................................................................................... 2-10  
[IP_ADDRESS].  Sirolimus (Rapamune) ...
............................................................................................ 2-10  
[IP_ADDRESS].  Tacrolimus (Prograf) ...
............................................................................................... 2-11  
[IP_ADDRESS].  Methotrexate ................................................................................................................ 2-13  
2.8.2.  Adverse Reactions............................................................................................................. 2-13  
[IP_ADDRESS].  Sirolimus ..................................................................................................................... 2-13  
[IP_ADDRESS].  Tacrolimus ................................................................................................................... 2-14  
[IP_ADDRESS].  Methotrexate ................................................................................................................ 2-14  
2.8.3.  Drug Interactions .............................................................................................................. 2-14  
[IP_ADDRESS].  Sirolimus ..................................................................................................................... 2-14  
[IP_ADDRESS].  Tacrolimus ................................................................................................................... 2-15  
[IP_ADDRESS].  Methotrexate ................................................................................................................ 2-15  
2.9. Management of Toxicities ............................................................................................... 2-16  
2.9.1.  GVHD .............................................................................................................................. 2-16  
2.9.2.  VOD ................................................................................................................................. 2-16  
2.9.3.  Idiopathic Pneumonia Syndrome/Diffuse Alveolar Hemorrhage ........................................ 2-[ADDRESS_646476] Hospi[INVESTIGATOR_3849] ......................................................................................... 3-2  
3.2.5.  Infections ............................................................................................................................ 3-2  
3.2.6.  CMV Reactivation .............................................................................................................. 3-2  
3.2.7.  Thrombotic Microangiopathy .............................................................................................. 3-2  
3.2.8.  VOD ................................................................................................................................... 3-2  
3.2.9.  Chronic GVHD ................................................................................................................... 3-3  
3.2.10.  Relapse of the Original Malignancy..................................................................................... 3-3  
3.2.11.  Survival .............................................................................................................................. 3-4  
4. PATIENT REGISTRATION, RANDOMIZATION AND ENROLLMENT .................. 4-1  
4.1. Approaching Patients, Eligibility Screening and Obtaining Consent ............................. 4-1  
4.2. Transplant Protocol Registration ..................................................................................... 4-1  
4.3. Randomization .................................................................................................................. 4-1  
4.4. Treatment Scheduling ....................................................................................................... 4-1  
4.5. Patient Evaluation............................................................................................................. 4-1  
4.5.1.  Recipi[INVESTIGATOR_501750] ........................................................................................................... 4-1  
4.6. Study Monitoring .............................................................................................................. 4-2  
4.6.1.  Patient Assessments ............................................................................................................ 4-2  
[IP_ADDRESS].  Pre-transplant evaluations .............................................................................................. 4-4  
[IP_ADDRESS].  Post-transplant evaluations ............................................................................................. 4-4  
4.6.2.  Case Report Forms .............................................................................................................. 4-5  
4.6.3.  Reporting Patient Deaths ..................................................................................................... 4-5  
4.6.4.  Reporting Serious Adverse Events....................................................................................... 4-5  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
v
i [IP_ADDRESS].  Patient SAEs .................................................................................................................. 4-[ADDRESS_646477] 
OF APPENDICES 
 
APPENDIX A SAMPLE TAPERING SCHEDULES FOR SIROLIMUS AND 
TACROLIMUS 
APPENDIX B INFORMED CONSENTS 
APPENDIX C LABORATORY SAMPLES 
APPENDIX D RECOMMENDED LEUCOVORIN RESCUE SCHEMA 
APPENDIX E CONSENSUS GVHD GRADING 
APPENDIX F MODIFIED OMAS SCORING SYSTEM SAMPLE CASE REPORT 
FORM 
APPENDIX G HUMAN SUBJECTS 
APPENDIX H GUIDELINES FOR SIMULTANEOUS USE OF SIROLIMUS AND 
ORAL VORICONAZOLE 
APPENDIX I REFERENCES 
 
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
1-1 CH
APTER 1 
 
 
1. BA
CKGROUND AND RATIONALE 
 
1.1. Allogeneic Stem Cell Transplantation 
 
Hematopoietic stem cell transplantation (HSCT) is an accepted therapy for hematologic 
malignancies, marrow failure, and some congenital disorders.  However, both transplant-related 
toxicity and graft-versus-host disease (GVHD) continue to be major problems that limit the 
general value of HSCT.   
 
Transplant-related toxicity results from the conditioning regimen and agents used to control 
GVHD.  Patient and donor age, disease remission status, number of prior chemotherapy 
regimens, comorbid diseases and many other factors influence short and long-term risks of 
transplant-related morbidity and mortality.  Modifications to the chemotherapeutic and GVHD 
prophylaxis agents that reduce transplant-related toxicity would be a welcome improvement. 
 
Acute GVHD results from a complex interaction of donor T cells and recipi[INVESTIGATOR_501751]/or minor histocompatibility antigens in an inflammatory 
milieu.  Clinical injury is thought to derive from direct T cell injury through perforin/granzyme, 
Fas/FasL interactions, and the effects of inflammatory cytokines.  The context of this recognition 
is a critical factor.  HSCT recipi[INVESTIGATOR_501752] a pro-inflammatory milieu for T cell recognition and 
activation.  This may in part be mediated through direct and indirect cytokine effects.  It is 
reasonable to propose that drugs that result in additional tissue injury may contribute to GVHD. 
They also clearly increase transplantation-related morbidity.   
 
Grade II-IV acute GVHD occurs in 35-40% of patients undergoing HLA-matched related donor 
stem cell transplantation1.  
Fifteen percent develop severe, Grade III-IV disease.  Approximately 
40% of patients with acute GVHD will have durable responses to corticosteroid therapy; there 
has been little change in this response rate over the past 20 years despi[INVESTIGATOR_501753]2.  
The prognosis for the 60% of 
patients without long-lasting responses is poor3. 
 A strategy that minimizes the incidence of 
GVHD, without other adverse effects, rather than improves treatment of established GVHD, seems more likely to improve overall survival after allogeneic transplantation. 
 
1.2. GVHD Prophylaxis 
GVHD can be prevented or decreased with a variety of pharmacologic agents
[ADDRESS_646478]-transplant methotrexate to 
prevent GVHD; in the 1980s cyclosporine was demonstrated to be superior to methotrexate and in [ADDRESS_646479] been developed as 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
1-2 GV
HD prophylactic agents because of favorable toxicity profiles in comparison with 
cyclosporine7. 
 As monotherapy for prevention of GVHD after allogeneic transplantation, 
tacrolimus has demonstrated safety and efficacy in rodent studies8 as
 well as in trials of human 
subjects9. 
   
 
Trials evaluating combination therapy as prophylaxis for GVHD in comparison with single agent 
therapy focused mainly on cyclosporine rather than tacrolimus.  The Seattle group initially 
demonstrated the superiority of cyclosporine/methotrexate over cyclosporine alone for GVHD 
prophylaxis6. 
 Since then, several trials have demonstrated the efficacy of adding a second agent 
to cyclosporine10, 11,
 12. 
 There are few studies evaluating single agent tacrolimus with tacrolimus-
based combination therapy.  However, in one small trial evaluating GVHD after peripheral blood stem cell transplantation, where GVHD rates may be higher than after bone marrow 
transplantation
13, 
no statistically significant increase in GVHD was noted in patients who 
received tacrolimus monotherapy in comparison with patients who received combination 
tacrolimus/methotrexate14. 
 The addition of a third agent to established 2-drug GVHD 
prophylaxis regimens has not shown a benefit15,
 16. 
 Larg
e Phase III studies comparing tacrolimus/methotrexate versus cyclosporine/methotrexate for 
both matched, related and unrelated donors have been performed.  In the matched, related donor 
setting, 329 patients were randomized to receive either tacrolimus/methotrexate or 
cyclosporine/methotrexate.  The incidence of Grade II-IV acute GVHD was 31.9% in the 
tacrolimus arm and 44.4% in the cyclosporine arm17.  
Similarly, in the unrelated donor study, the 
incidence of Grade II-IV acute GVHD was 56% among the 46 patients randomized to tacrolimus and was 74% among the [ADDRESS_646480] 
common form of GVHD prophylaxis in the HLA-identical sibling and unrelated donor settings, however, the use of tacrolimus and tacrolimus-based regimens is increasing.  Table 1.2 
demonstrates current GVHD prophylaxis agent use, according to a recent Center for 
International Blood and Marrow Transplant Research (CIBMTR) analysis.   
 
 
Table 1.2 – Current Use of GVHD Regimens, as Reported to the IBMTR 
 
Regimen Matched, Related Donor
 Unrelate
d Donor 
Methotrexate alone 4% 1% 
Cyclo
sporine alone 6% 2% 
Tacrolimus ± other 5% 6% 
Cyclosporine ± other 6% 27% 
Cyclosporine, Methotrexate ± other 42% 32% 
Tacrolimus, Methotrexate ± other 24% 24% 
T cell depletion ± other 10% 5% 
Other 2% 4% 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646481].  It has been 
shown to complement the effects of cyclosporine in preventing severe GVHD6.  
However, it also 
may increase the risk of other complications such as mucositis and hemorrhagic pneumonia/interstitial pneumonitis
21 and
 as a consequence, may increase the incidence of GVHD 
through tissue injury22, 23. 
 Methotrexate is an antiproliferative agent and is associated with 
slower recovery of neutrophils after allogeneic transplantation.  In a retrospective study of peripheral blood stem cell transplantation trials, the use of full-dose methotrexate was associated 
with a 2.5 day median delay in the time to neutrophil engraftment
24. 
  
 
1.3. Sirolimus 
 Sirolimus (Rapamune
®, 
Wyeth) is a naturally occurring compound originally isolated from a soil 
saprophyte (Streptomyces hygroscopi[INVESTIGATOR_361])  found uniquely on Easter Island (Rapa Nui).   In 
addition to its immunosuppressive properties, sirolimus has antifungal, antiviral and 
antineoplastic properties. 
 
Although structurally similar to calcineurin inhibitors, sirolimus binds uniquely to FK binding 
protein 12 (FKBP12) and then complexes with mTOR (mammalian Target of Rapamycin).  
Sirolimus does not interact with calcineurin or its downstream effectors.  The sirolimus-
FKBP12-mTOR complex inhibits several distinct biochemical pathways, resulting in a reduction 
in DNA transcription, DNA translation, protein synthesis and cell cycling, ultimately leading to 
T cell immunosuppression.  Upstream pathways that interact with mTOR include the PTEN/pI3 
kinase/Akt pathway and the Janus kinase pathway, which is important in mediating IL-[ADDRESS_646482] that the combination of sirolimus and 
tacrolimus is more effective than the combination of sirolimus and cyclosporine in reducing 
memory T cell production, apoptosis induction and cytokine production39. 
 When tested in a 
comparative fashion after renal transplantation, early results suggested fewer epi[INVESTIGATOR_501754]40,
 41. 
 The use of combination immunosuppression with sirolimus in stem cell 
transplantation is attractive, since the drug has non-overlappi[INVESTIGATOR_501755] a different mechanism of action. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
1-4  1.3
.1. Preliminary Experience with Sirolimus in Stem Cell Transplantation 
 
[IP_ADDRESS].  Therapy of established GVHD 
 
In the only published report on therapy of established steroid-refractory acute GVHD, Benito et 
al described their experience treating [ADDRESS_646483] patients were treated with 
4-5 mg/m2/
day after an oral loading dose of 15 mg/m2. 
 Although the drug was active in this 
patient population (overall response rate 57%), the drug proved to be too toxic at the doses used.  
Five patients developed thrombotic microangiopathy and many others had reversible 
cytopenias42. 
 
T
he efficacy of sirolimus as therapy for chronic GVHD in combination with calcineurin 
inhibitors has been published in abstract only.   Johnston et al described a 56% overall response 
rate when sirolimus was given with either tacrolimus or cyclosporine in patients with established 
chronic GVHD43, 
while Couriel et at  described a 68% response rate to the combination of 
sirolimus and tacrolimus in patients with steroid-refractory chronic GVHD44. 
 1.3
.1.2. Prophylaxis of GVHD 
 
Unrelated Donor Transplantation  
A
t the Dana-Farber Cancer Institute, 65 patients (median age 39.5 years, range 19-62) have 
undergone HLA-matched unrelated and single HLA-antigen mismatched related and unrelated 
bone marrow transplantation using the combination of sirolimus, tacrolimus and abbreviated 
methotrexate as GVHD prophylaxis.  Presumably due to a reduction in methotrexate dose, rapid 
neutrophil and platelet engraftment was noted.  The oral formulation of sirolimus was tolerated 
and patients maintained adequate serum levels during the trial (sirolimus 3-12 ng/mL, tacrolimus 
5-10 ng/mL).  Among the first 41 patients analyzed as part of a Phase II clinical trial, the 
incidence of Grade II-IV acute GVHD was 26% and the incidence of Grade III-IV acute GVHD 
was 13%.  Overall, the combination was safe with only moderate transplant-related toxicity.  
Overall survival for the entire group of patients (n=65) at one year is 56% and at 2 years is 50% 
in this high-risk population45. 
  
 
Related Donor Transplantation  
A
t the Dana-Farber Cancer Institute, over 50 patients (median age 41 years, range 18-59) have 
undergone HLA-matched, related peripheral blood stem cell transplantation using the combination of sirolimus and tacrolimus without methotrexate.  The hypothesis tested in this trial 
was that the omission of methotrexate would not increase the rate of GVHD and would reduce 
transplant-related toxicity.  To date, sirolimus has been well tolerated and oral administration has 
been effective in attaining and maintaining adequate serum drug levels.  Among the first 38 
patients followed for greater than 100 days, the median times to neutrophil and platelet 
engraftment were 14 days (range 11 to 17 days) and 13 days (range 10 to 47 days), respectively.  
Platelet engraftment occurred sooner in comparison with recent IBMTR analyses (13 vs. 18 
days, unpublished data).  The rates of Grade II-IV and III-IV acute GVHD were 16% and 5%, 
respectively, at 100 days.  Transplant-related toxicity has been limited: 4 patients developed 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
1-5 se
vere veno-occlusive disease of the liver (11%) and no patient developed idiopathic pneumonia 
syndrome.  CMV reactivation rates were low (<10%) and no patient developed an invasive 
fungal infection during the first 100 days after transplantation when prophylactic antifungal 
agents were not used.  Thrombotic microangiopathy occurred in 4 patients (11%); it resolved in 
all cases when tacrolimus was discontinued.  Transplant-related mortality at 100 days was 5%. 
Overall survival at 1 year is 72%46, 
now with a median follow-up of 13 months.  A summary of 
the major clinical results along with results from the randomized trial that compared 
tacrolimus/methotrexate with cyclosporine/methotrexate is found in Table 1.3.     
 
 
Table 1.3 – Clinical Outcomes Associated With Alternate GVHD Prophylaxis Regimens 
After Matched, Related Allogeneic Stem Cell Transplantation 
 
 Tacrolimus/ 
Sirolimus Tacrolimus/ 
Methotrexate Cyclosporine/ 
Methotrexate 
Sample Size 38 165 164 
Med
ian Age (range) 41 (19-59) 40 (17-61) 40 (16-63) 
%
 Male 50 56 61 
Ste
m Cell Source PBSC BM BM 
Ne
utrophil Recovery (median days) 14 19  20  
GV
HD (%)    
  
 Acute Grade II-IV 16 31.9 44.4 
  
 Acute Grade III-IV 5 13.3 17.1 
  
 Chronic 31 55.9 49.4 
Surv
ival (%)    
  
 100-Day Treatment-Related Mortality  5 32 21 
  
 1 Year Relapse-Free Survival 69 47 58 
  
 1 Year Overall Survival 72 52 64 
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-1 CH
APTER 2 
 
 
2. STUDY D
ESIGN 
 
2.1. Study Overview 
 
This is a Phase III randomized, open label, multicenter clinical trial sponsored by [CONTACT_501799] (BMT CTN).  The objective of the trial is to test the 
null hypothesis that there is no difference in acute GVHD-free survival at [ADDRESS_646484]-randomization.  
Secondary analyses will consider neutrophil and platelet recovery, time to hospi[INVESTIGATOR_2345], 
acute and chronic GVHD, relapse, infections, adverse events (mucositis, thrombotic 
microangiopathy and CMV reactivation) and overall survival.  Accrual is anticipated for three 
years with a follow-up period of two years. 
 
2.2. Hypothesis and Study Objectives 
 
2.2.1.  Primary Hypothesis 
 
The primary hypothesis to be tested in this randomized, controlled trial is that the combination of 
sirolimus and tacrolimus (study group) will result in a 15% improvement in 114-day Grades II-
IV acute GVHD-free survival from the time of randomization in comparison to the combination 
of tacrolimus and methotrexate (control group) after myeloablative HLA-matched, related donor 
allogeneic peripheral blood stem cell transplantation for acute myelogenous leukemia (AML), 
acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML) or myelodysplastic 
syndrome (MDS).  
 
2.2.2.  Secondary Hypotheses 
 
Secondary hypotheses to be tested in this clinical trial include:  
 Stable neutrophil and platelet engraftment will occur sooner with study therapy;  
 Hospi[INVESTIGATOR_501756];  
 Incidence of Grades II-IV and III-IV of acute GVHD will be lower in the study group; 
 Mucositis incidence and severity will be reduced with study therapy;  
 Infectious events will be less frequent in the study group; 
 CMV reactivation will be less frequent in the study group;  
 Chronic GVHD incidence will be lower in the study group; and, 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-2  Re
lapse-free and overall survival will be higher in the study group. 
 
2.2.3.  Primary Objective 
 
The primary objective is to compare rates of 114-day Grades II-IV acute GVHD-free survival 
post randomization for HLA-matched, related donor allogeneic peripheral blood stem cell 
transplantation using two different GVHD prophylaxis regimens.  
 
2.2.4.  Secondary Objectives 
 Secondary objectives are to compare patients receiving sirolimus and tacrolimus with those 
receiving methotrexate and tacrolimus for: 
1. Time to stable neutrophil and platelet engraftment after transplantation; 
2. Incidences of Grades III-IV acute GVHD; 
3. Mucositis severity; 
4. Time to first hospi[INVESTIGATOR_2345]; 
5. Incidence of infections in the first [ADDRESS_646485]-transplantation; 
6. CMV reactivation in the first [ADDRESS_646486]-transplantation; 
7. Thrombotic microangiopathy incidence in the first [ADDRESS_646487]-transplantation; 
8. VOD incidence in the first [ADDRESS_646488]-transplant; 
9. Incidence of chronic GVHD; 
10. Relapse of primary malignant disease in distinct disease subgroups; and, 
11. 1-year relapse-free and overall survival. 
 2.3. Patient Eligibility for Randomization 
 
2.3.1.  Patient Eligibility for Randomization 
 
Diagnoses to be included: 
1. Acute Myelogenous Leukemia at the following stages: 
 First Remission 
 Second or subsequent remission 
Complete remission is defined as the absence of blasts in the peripheral circulation at 
the time of enrollment and < 5% blasts in the marrow within 28 days of enrollment.  
2. Acute Lymphoblastic Leukemia at the following stages: 
 First Remission 
 Second or subsequent remission 
Complete remission is defined as the absence of blasts in the peripheral circulation at 
the time of enrollment and < 5% blasts in the marrow within 28 days of enrollment. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-3 3. Ac
ute Biphenotypic Leukemia at the following stages: 
 Fi
rst remission 
 Second or
 subsequent remission 
Complete remission is defined as the absence of blasts in the peripheral circulation at 
the time of enrollment and < 5% blasts in the marrow within 28 days of enrollment. 
4. Chronic Myelogenous Leukemia at the following stages: 
 First or Subsequent Chronic Phase: 
o Stable, not hematologic remission: blasts present in marrow and/or peripheral 
blood, but disease does not qualify as accelerated or blast phase 
o Hematological remission: no blast cells or precursor cells in the blood or marrow 
o Partial cytogenetic remission: Ph+ metaphases > 0% but < 35% 
o Complete cytogenetic remission: absence of Ph+ metaphases 
 Accelerated Phase - any one of the following symptoms: 
o WBC difficult to control (> 50 x 109/L d
espi[INVESTIGATOR_116175]) 
o Rapid doubling of WBC (< 5 days) 
o 10% blasts in blood or marrow 
o 20% blasts and/or promyelocytes in blood or marrow 
o 20% basophils and/or eosinophils in blood 
o Anemia or thrombocytopenia unresponsive to standard treatment 
o Persistent thrombocytosis (> 1000 x 109/L) 
o Cy
togenetic abnormalities in addition to Ph+ 
o Increasing splenomegaly 
o Marrow fibrosis 
5. Myelodysplastic syndromes at any of the following stages: 
 Refractory anemia 
 Refractory anemia with ringed sideroblasts 
 Refractory cytopenia with multilineage dysplasia 
 Refractory cytopenia with multilineage dysplasia and ringed sideroblasts 
 Refractory anemia with excess blasts-1 (5-10% blasts) 
 Refractory anemia with excess blasts-2 (10-20% blasts) 
 Myelodysplastic syndrome, unclassified 
 MDS associated with isolated del (5q)  
 Chronic Myelomonocytic Leukemia 
 
Other eligibility criteria include: 
1. 6/6 HLA-matched sibling, defined by [CONTACT_130039] I (HLA-A and B) serologic typi[INVESTIGATOR_007] (or higher 
resolution) and Class II (HLA-DRBI) molecular typi[INVESTIGATOR_501757].  The donor must be 
medically eligible to donate stem cells according to individual transplant center criteria.  
Pediatric patients in whom a pediatric sibling donor is not anticipated to be a suitable 
leukapheresis candidate are not eligible. 
2. Karnofsky ≥ 70% or Lansky performance status ≥ 70% for patients < 16 years old at time 
of registration. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-4 3. Ag
e range: 2.0 – 60.0 years at time of registration. 
4. For children less than age 18, willingness and ability to take oral medications per the 
treating physician.  
5. Signed informed consent. 
 2.3.2.  Patient Exclusion Criteria 
 
Patients will be excluded from this trial if they meet the following criteria: 
1. Prior allogeneic or autologous transplants using any hematopoietic stem cell source. 
2. Seropositive for the human immunodeficiency virus (HIV). 
3. Uncontrolled bacterial, viral or fungal infections (currently taking medication and 
progression of clinical symptoms). 
4. Pregnancy (positive serum β-HCG) or breastfeeding.  
5. Renal function: Serum creatinine outside the normal range for age; or calculated creatinine clearance < 50 mL/min/1.72m
2. 
6. Hepati
c function: Most recent direct bilirubin, ALT or AST greater than two times the 
upper limit of normal for the laboratory. 
7. Pulmonary disease: In adults, FVC or FEV1 < 60% predicted (corrected for hemoglobin).  
In children, overt hypoxemia as measured by [CONTACT_501800] < 92%. 
8. Cardiac ejection fraction < 45% in adults and children, or < 26% shortening fraction in children. 
9. Cholesterol > 500 mg/dL or Triglycerides > 500 mg/dL while being treated or not on 
appropriate lipid-lowering therapy.  
10. Patient with prior history of allergy to sirolimus. 
11. Patient requiring voriconazole at time of study registration. 
12. Patients receiving another investigational drug unless cleared by [CONTACT_501801]. 
13. Patients with prior malignancies except resected basal cell carcinoma or treated 
carcinoma in-situ.  Cancer treated with curative intent > 5 years previously will be 
allowed.  Cancer treated with curative intent < 5 years previously will not be allowed 
unless approved by [CONTACT_126391]. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-5 2.4
. Conditioning 
 
Two groups of myeloablative conditioning regimens will be allowed: 
1. Cyclophosphamide and Total Body Irradiation (CY-TBI) with a TBI dose of at least  
1200 cGy of fractionated TBI*.  
2. Etopo
side and Total Body Irradiation (VP16-TBI) with a TBI dose of at least [ADDRESS_646489] declare before randomization what 
conditioning regimen will be used for each patient.  The specified regimens will be used for the 
patient whether randomized to receive sirolimus/tacrolimus or tacrolimus/methotrexate. 
 
2.4.3.  Order of Administration of TBI and Cyclophosphamide 
 
The order of administration of cyclophosphamide and TBI is at the discretion of the transplant 
center.  Within each institution, all patients should receive the cyclophosphamide and TBI in the 
same order.  If cyclophosphamide or VP16 is given last, there should be at least a one-day rest 
period before the peripheral blood stem cell infusion. 
 
[IP_ADDRESS].  TBI administration 
 
Fractionated TBI will be administered according to the institutional protocol.  The Institution 
will also define radiation sources, dose rates, details of lung shielding and sites receiving boost 
radiation.  TBI may be delivered from either linear accelerator or Cobalt sources.  Lung shielding 
is preferred but not required during TBI.   
 
[IP_ADDRESS].  Cyclophosphamide administration 
 
Cyclophosphamide will be administered intravenously.  Mesna is allowed, but not required. 
 
                                                  
 
* T
he conditioning regimen, from which the Phase II data is derived, is comprised of Cytoxan 1800 mg/m2 x 2 dose
s 
and TBI 14 Gy in 7 fractions with lung shielding. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-6 2.5
. Stem Cell Transplantation 
 
2.5.1.  Stem Cell Collection 
 
HLA-matched sibling donors will undergo G-CSF mobilization according to local institutional 
practices.  Peripheral blood stem cells will be collected by [CONTACT_501802].  Plasma and red cell depletion are allowed for volume reduction or 
ABO incompatibility but any other form of graft manipulation (including ex-vivo T cell 
depletion) is not permitted. 
 
The target stem cell dose is between 2 x 106/kg 
and 10 x 106/kg 
(actual body weight) CD34+ 
s
tem cells.    
 
Up to two leukapheresis procedures may be performed to obtain the minimum CD34+ st
em cell 
target.  If, after two leukapheresis procedures, fewer than 2 x 106/kg CD3
4+ s
tem cells have been 
collected, transplant centers will have the discretion to continue peripheral blood stem cell 
harvesting or to proceed to bone marrow harvesting to obtain sufficient stem cells.  Regardless of 
the decision, subjects will be followed and analyzed with their treatment assignment group in an 
intent-to-treat manner. 
 
If more than 10 x 106/kg CD3
4+ s
tem cells are collected, the excess should either be discarded or 
cryopreserved for future use, but should not be administered to the patient. 
 
2.5.2.  Stem Cell Administration 
 
Peripheral blood stem cells will be administered on Day 0 to all patients according to individual 
institutional guidelines after appropriate processing and quantification has been performed by [CONTACT_12389].  Stem cells are administered through an indwelling central venous catheter.  If 
infusion occurs over two days, Day 0 is the day infusion is completed. 
 
2.6. GVHD Prophylaxis  
 
This is a randomized, controlled clinical trial comparing two GVHD prophylaxis regimens:  
sirolimus/tacrolimus and tacrolimus/methotrexate.  All patients will be randomly assigned to one 
of the two GVHD prophylaxis regimens.  GVHD prophylaxis begins on Day –3.  Blinding will 
not be performed.  All patients will be analyzed with their treatment assignment group (intent-to-
treat analysis).  
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-7 2.6
.1. Sirolimus/Tacrolimus 
 
[IP_ADDRESS].  Dosing 
 
Adults : 
Sirolimus will be given in a loading dose of 12 mg on Day –[ADDRESS_646490] vomits within 15 minutes of an oral 
dose.   
 
Children:  Chil
dren aged < 12.0 years OR weighing < 40.0 kg will be given an oral loading dose 
of sirolimus of 3 mg/m2 f
ollowed by a daily oral dose of 1 mg/m2, 
rounded to the nearest full 
milligram.  
Adults and Children
: 
 Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a 
continuous intravenous infusion beginning on Day –3.  An effort will be made to convert the 
tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given 
every 12 hours as soon as clinically feasible.    
 
[IP_ADDRESS].  Monitoring 
 
Levels of sirolimus and tacrolimus will be drawn at least twice per week while hospi[INVESTIGATOR_057], then 
weekly or monthly thereafter unless a change in medication (e.g. use of itraconazole) or renal 
function might result in an acute change in level.  At that point levels will be measured as 
clinically indicated.  Levels of sirolimus must be assayed by [CONTACT_501803]-MS.  ELISA or 
other immunoassays are not permitted.  Tacrolimus level is measured according to local 
institutional practices. 
 
[IP_ADDRESS].  Target serum levels and dose modifications 
 
The target serum level for sirolimus is 3-12 ng/mL. 
 
Dose adjustments are based on clinical judgment of the treating physician after considering 
clinical toxicity, serum levels, GVHD, concomitant drug use and the rate of rise or decline of the 
serum level.  For levels < 3 ng/mL, it is suggested, but not required, that the dose of sirolimus be 
increased by [CONTACT_3450] 25% increments no more frequently than every [ADDRESS_646491] full milligram until the target range is achieved.  Conversely, for levels > 12 ng/mL, it 
is suggested, but not required, that the dose be decreased by [CONTACT_3450] 25% no more 
frequently than every 2 days until the target level is achieved.  Alternatively, sirolimus can be 
held entirely as long as serum levels are monitored and the drug is restarted when the level 
returns to the therapeutic range and the treating physician feels it is appropriate to restart the 
agent. 
 
The target serum level for tacrolimus is 5-10 ng/mL. 
 
Dose adjustments are based on clinical judgment of the treating physician after considering 
clinical toxicity, serum levels, GVHD, concomitant drug use and the rate of rise or decline of the 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-8 serum
 level.  For levels < 5 ng/mL, it is suggested, but not required, that the dose of tacrolimus 
be increased by [CONTACT_3450] 25% increments every 1-[ADDRESS_646492]  
0.5 milligram (when dosing is oral) until the target range is achieved.  Conversely, for levels  
> 10 ng/mL, it is suggested, but not required, that the dose of tacrolimus be decreased by 
[CONTACT_3450] 25% every 1-2 days until the target level is achieved.  Alternatively, tacrolimus 
can be held entirely as long as serum levels are monitored and the drug is restarted when the 
level returns to the therapeutic range and the treating physician feels it is appropriate to restart 
the agent. 
 
[IP_ADDRESS].  Tapering 
 
Tapering of sirolimus and tacrolimus will begin at Day 100 in the absence of GVHD and disease 
relapse.  The goal of tapering is the complete discontinuation of immunosuppressant medications 
by 6 months.  Sirolimus and tacrolimus should be tapered in an alternating fashion every other 
week when clinically feasible.  Similar reductions in dosages should be employed for each drug 
at each tapering event, with modifications at the end of the tapering schedule to allow near 
simultaneous discontinuation of sirolimus and tacrolimus.  Sample tapering schedules for adults 
and children are found in Appendix A. 
 
2.6.2.  Tacrolimus/Methotrexate 
 
[IP_ADDRESS].  Dosing 
 Dosing of tacrolimus is as described in Section [IP_ADDRESS] above. 
 
Methotrexate will be given at a dose of 15 mg/m
2 on 
Day 1 after transplantation, and at a dose of 
10 mg/m2
 on 
Days 3, 6 and 11 after transplantation.  Attempts should be made to administer all 
four doses of methotrexate.  Omission of any of the doses of methotrexate is at the treating physician’s discretion, will not be considered a protocol violation, but will be recorded as a 
deviation from the planned GVHD prophylaxis regimen.   
 
Leucovorin rescue may be given at the treating physician’s discretion.  Patients at risk for 
methotrexate toxicity include those with large fluid collections (ascites, pleural effusions) or with 
decreased renal function.  A recommended leucovorin rescue schema can be found in Appendix 
D. 
 
[IP_ADDRESS].  Monitoring 
Levels of tacrolimus will be drawn at least twice per week while hospi[INVESTIGATOR_057], then weekly or 
monthly thereafter unless a change in medication (e.g. use of itraconazole) or renal function 
might result in an acute change in level.  At that point levels will be measured as clinically 
indicated.   
 
[IP_ADDRESS].  Target serum levels and dose modification 
 Target dosing and dose modifications for tacrolimus are as described in Section [IP_ADDRESS] above. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-9  2.6
.2.4. Tapering 
 
Tapering of tacrolimus is as described in Section [IP_ADDRESS] above.  Tapering should commence at 
Day 100 in the absence of GVHD and disease relapse.  The goal of tapering is the complete 
discontinuation of immunosuppressant medications by [CONTACT_157515].  Tacrolimus should be 
tapered every other week when clinically feasible.  Similar reductions in dosages should be 
employed at each tapering event, to allow complete discontinuation by [CONTACT_157515].  
 
2.7. Supportive Care 
 
All supportive care will be given in keepi[INVESTIGATOR_501758] (MOP) and 
local institutional practice.  Supportive care should be administered in a similar fashion to 
subjects randomized to both arms of the study. 
 
2.7.1.  Growth Factors 
 
Growth factors will not be used following transplant unless absolute neutrophil cell count (ANC) 
recovery to 0.5x109/L 
has not occurred by [CONTACT_2006] +14.  If by [CONTACT_2006] +14, the ANC is still < 0.5x109/L
 
or if, after initial recovery, the ANC drops below 1 x 109/L,
 G-CSF may be given per 
institutional guidelines.  
2.7.2.  Blood Products 
 
Transfusion thresholds for blood product support will be consistent with BMT CTN MOP and 
standard institutional guidelines.  All blood products will be irradiated.  Patients who are CMV 
negative will receive CMV negative or filtered blood products from study entry. 
 
2.7.3.  Prophylaxis Against Infections 
 
All patients will receive prophylaxis against bacterial, fungal and viral infections during the peri-
transplant period according to the BMT CTN MOP.  Prophylaxis must be the same for patients 
on both arms of the protocol.  This will include: 
1. Anti-bacterial prophylaxis: In keepi[INVESTIGATOR_501759].  Prophylactic antibacterial antibiotics should be used for patients during the neutropenic (ANC < 500/mcL) period. 
2. Pneumocystis carinii: Prophylaxis will start at the time of hospi[INVESTIGATOR_501760] [ADDRESS_646493]-transplant according to institutional practice.  Prophylaxis should be continued 
according to institutional practices. 
3. Antifungal therapy: Prophylaxis with fluconazole or other antifungal agents can be given 
as per local institutional guidelines.  Fluconazole and other azoles are expected to 
increase serum tacrolimus and sirolimus levels, therefore, dosages of sirolimus and 
tacrolimus should be adjusted accordingly.  Due to extreme interactions with 
sirolimus, voriconazole is contraindicated during sirolimus therapy and should not 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646494] antifungal prophylaxis and should not be used as prophylaxis in the tacrolimus/methotrexate arm; however, in the event of suspected 
or documented fungal infection, voriconazole may be used in this study arm if 
deemed clinically necessary.  For guidelines on the simultaneous use of sirolimus 
and oral voriconazole, see Appendix H.  
4. HSV/VZV: Prophylaxis will begin with conditioning therapy and continue up to the time 
of discharge.  At that time, prophylaxis should continue as per institutional guidelines.   
5. CMV: Monitoring and preemptive or prophylactic treatment strategy will be in accordance with the BMT CTN MOP and local institutional practice. 
 
2.7.4.  Intravenous Immune Globulin (IVIG) 
 
IVIG administration will be left to local institutional standard practice. 
 
2.7.5.  Kepi[INVESTIGATOR_501761], but not recommended because mucositis assessment is a secondary 
endpoint to the protocol. 
 
2.8. Description of Study Drugs 
 
2.8.1.  Administration and Storage 
 
[IP_ADDRESS].  Sirolimus (Rapamune
) 
 
Si
rolimus will be provided by [CONTACT_501804]. 
 
Similar to the calcineurin inhibitors, sirolimus has low oral bioavailability due to first pass 
metabolism by [CONTACT_501805], P-glycoprotein (P-gp).  The 
median t m
ax v
alue for the oral suspension is < 1 hour indicating that there is rapid absorption. 
However, systemic availability is ~14% in stable renal transplant patients.  Total body clearance 
is 127 to 240 mL/hr/kg and is not related to dose.   Half-life is 57 to 63 hours.  It is extensively 
bound by [CONTACT_501806].  It is excreted by [CONTACT_501807].  In 
Phase III studies, whole blood trough levels for a 2 mg/day dose were 8.59  4.01 ng/mL and 
correlate with the AUC (r2=0
.95). Only ~2% is excreted in the urine.   
 
The mean bioavailability of sirolimus after administration of the tablet is about 27% higher 
relative to the oral solution.  Sirolimus oral tablets are not bioequivalent to the oral solution; 
however, clinical equivalence has been demonstrated at the 2-mg dose level.  Differences in 
absorption kinetics and bioavailability in renal transplant patients are shown in Table 2.8a 
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-1
1 Ta
ble 2.8a – Sirolimus Pharmacokinetics 
 
Formulation, 
2 mg Cm
ax,ss 
(n
g/mL) tm
ax 
(h
) AUC 0 
(n
gh/mL) CL/F/WT 
(mL/h/kg) 
Oral S
olution  14.4 ± 5.3 2.12 ± 0.84 194 ± 78 173 ± 50 
T
ablet 15.0 ± 4.9 3.46 ± 2.40 230 ± 67 139 ± [ADDRESS_646495] the excretion of sirolimus, but excretion is reduced in liver failure as 
shown in Table 2.8b. 
 
Table 2.8b – Sirolimus Pharmacokinetics in Hepatic Impairment 
 
Population Cm
ax,ss 
(n
g/mL) tm
ax 
(h
) AUC 0 
(n
gh/mL) CL/F/WT  
(m
L/h/kg) 
He
althy Subjects 78.2  18.3 0.83  0.17 970  272 215  76 
Hepati
c Impairment 77.9  23.1 0.84  0.17 1567  616 4  62 
 
 
Si
rolimus oral solution : 
Sirolimus oral solution (bottles and foil pouches) should be stored 
protected from light and refrigerated at 2 C to 8C (36F to 46F).  For dilution, the appropriate 
dose of sirolimus oral solution should be measured using an amber oral syringe.  The dose 
should be added to a glass or plastic container that holds at least 60 milliliters (mL).  Before 
taking the dose, it should be diluted with water or orange juice; IT SHOULD NOT BE 
DILUTED WITH GRAPEFRUIT JUICE.  After mixing with the diluent, the dose should be 
taken immediately.  The syringe should be discarded after one use.  Sirolimus oral solution 
provided in bottles may develop a slight haze when refrigerated.  If such a haze occurs allow the 
product to stand at room temperature and shake gently until the haze disappears.  The presence 
of this haze does not affect the quality of the product. 
 
Sirolimus tablets :
  Sirolimus tablets are available as white triangular shaped tablets marked 
“RAPAMUNE 1 mg” in bottles of 100 tablets or as cartons containing ten blister cards of ten 
tablets each.  Sirolimus tablets should be stored at 20° to 25°C (68°-77°F).  Cartons should be 
used to protect the blister cards and strips from light.  Sirolimus tablets should be dispensed in a 
tight, light-resistant container.  
 
[IP_ADDRESS].  Tacrolimus (Prograf) 
 
T
he pharmacokinetic parameters of tacrolimus have been determined following intravenous and 
oral administration in healthy volunteers, kidney transplant and liver transplant patients. 
Pharmacokinetic parameters for healthy volunteers are found in the Table 2.8c. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-1
2 Ta
ble 2.8c – Tacrolimus Pharmacokinetics 
 
 P
arameters 
P
opulation N Route, Dose Cm
ax 
(n
g/mL) tm
ax 
(h
r) AUC 
(ng*h/mL) t½    
   (h
r) Cl   (L/hr/kg) V     (L/kg) 
Heal
thy 
Volunteers 8 Iv 
(0.025 mg/kg/4hr) --- --- 598±125* 34.
2±7.7 0.04±0.009 1.91±0.31 
16 p
o (5 mg) 29.7±7.2 1.6±0.7  243±
73*
* 34.
8±11.4 0.041±0.008  
*
** 1.9
4±0.53 
*
** 
*
 AUC 0-12
0  *
* AUC 0-72   *
** Corrected for individual bioavailability 
 
Ab
sorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete 
and variable.  The absolute bioavailability of tacrolimus was 17 ± 10% in adult kidney transplant 
patients (N=26), 22 ± 6% in adult liver transplant patients (N=17), and 18 ± 5% in healthy 
volunteers (N=16).  
 
A single dose study conducted in 32 healthy volunteers established the bioequivalence of the 1 
mg and 5 mg capsules.  Another single dose study in 32 healthy volunteers established the 
bioequivalence of the 0.5 mg and 1 mg capsules.  Tacrolimus maximum blood concentrations  
(Cm
ax) 
and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 
fasted healthy volunteers receiving a single oral dose of 3, 7 and 10 mg.  In 18 kidney transplant 
patients, tacrolimus trough concentrations from 3 to 30 ng/mL measured at 10-[ADDRESS_646496]-
dose (C mi
n) 
correlated well with the AUC (correlation coefficient 0.93). In 24 liver transplant 
patients over a concentration range of 10 to 60 ng/mL, the correlation coefficient was 0.94.  The rate and extent of tacrolimus absorption were greatest under fasted conditions.  The presence and 
composition of food decreased both the rate and extent of tacrolimus absorption when 
administered to [ADDRESS_646497] pronounced with a high-fat meal 
(848 kcal, 46% fat): mean AUC and C
m
ax we
re decreased 37% and 77%, respectively; T m
ax w
as 
lengthened 5-fold.  A high-carbohydrate meal (668 kcal, 85% carbohydrate) decreased mean 
AUC and mean C m
ax b
y 28% and 65%, respectively.  In healthy volunteers (N=16), the time of 
the meal also affected tacrolimus bioavailability.  When given immediately following the meal, 
mean C m
ax w
as reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition.  
When administered 1.5 hours following the meal, mean C m
ax w
as reduced 63%, and mean AUC 
was reduced 39%, relative to the fasted condition.  In 11 liver transplant patients, tacrolimus 
administered 15 minutes after a high fat (400 kcal, 34% fat) breakfast, resulted in decreased 
AUC (27 ± 18%) and C m
ax (50
 ± 19%), as compared to a fasted state.  
 
The plasma protein binding of tacrolimus is approximately 99% and is independent of 
concentration over a range of 5-50 ng/mL.  Tacrolimus is bound mainly to albumin and alpha-1-
acid glycoprotein, and has a high level of association with erythrocytes.  The distribution of 
tacrolimus between whole blood and plasma depends on several factors, such as hematocrit, 
temperature at the time of plasma separation, drug concentration, and plasma protein 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-1
3 c
oncentration.  In a U.S. study, the ratio of whole blood concentration to plasma concentration 
averaged 35 ng/mL (range 12 to 67).  
 
Tacrolimus injection must be diluted with 0.9% Sodium Chloride Injection or 5% Dextrose 
Injection to a concentration between 0.004 mg/mL and 0.02 mg/mL prior to use.  Diluted 
infusion solution should be stored in glass or polyethylene containers and should be discarded 
after 24 hours.  The diluted infusion solution should not be stored in a PVC container due to 
decreased stability and the potential for extraction of phthalates. In situations where more dilute 
solutions are utilized (e.g., pediatric dosing, etc.), PVC-free tubing should likewise be used to 
minimize the potential for significant drug adsorption onto the tubing.  Parenteral drug products 
should be inspected visually for particulate matter and discoloration prior to administration, 
whenever solution and container permit.  Due to the chemical instability of tacrolimus in alkaline 
media, tacrolimus injection should not be mixed or co-infused with solutions of pH 9 or greater 
(e.g., ganciclovir or acyclovir).  Supplied as a sterile solution in 1-mL ampoules containing the 
equivalent of 5 mg of anhydrous tacrolimus per mL, in boxes of 10 ampoules.  Store between 
5°C and 25°C (41°F and 77°F).  Tacrolimus capsules (1 and 5 mg) are stored at controlled room 
temperature, 15°C-30°C (59°F-86°F).  
 
[IP_ADDRESS].  Methotrexate 
 
Methotrexate sodium for injection should be reconstituted with an appropriate sterile, 
preservative free medium such as 5% dextrose solution, USP, or sodium chloride injection, USP.  
Reconstitute the 20 mg vial to a concentration no greater than 25 mg/mL.  The 1 gram vial 
should be reconstituted with 19.4 mL to a concentration of 50 mg/mL.  Reconstitute immediately 
prior to use.  When high doses of methotrexate are administered by [CONTACT_16228], the total dose is 
diluted in 5% dextrose solution. 
 
Each 20 mg and 1 g vial of lyophilized powder contains methotrexate sodium equivalent to 20 
mg and 1 g methotrexate respectively.  Store at controlled room temperature, 20°-25° C  
(68°-77° F); excursions permitted to 15°-30° C (59°-86° F).  Protect from light. 
 
2.8.2.  Adverse Reactions 
 
[IP_ADDRESS].  Sirolimus 
 
Despi[INVESTIGATOR_501762], sirolimus is not associated with 
neurotoxicity or nephrotoxicity because of its inability to inhibit calcineurin.  Phase III clinical 
trials have indicated that the primary toxicities are hypertriglyceridemia, hypercholesterolemia, 
mild thrombocytopenia, anemia, leukopenia, hypokalemia, elevated LDH, arthralgia, epi[INVESTIGATOR_3940], 
edema, and infections.  Clinically significant elevations in hepatic transaminases without 
sequelae were noted in the prior Phase II study with this drug.  However, the incidence of veno-
occlusive disease of the liver was not noted to be higher than expected in trials of unrelated 
transplantation.  A syndrome of thrombotic microangiopathy, comprised of microangiopathic 
hemolytic anemia, thrombocytopenia and renal dysfunction has been described in association 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646498]-transplant lymphoproliferative disorders. 
 
[IP_ADDRESS].  Tacrolimus 
 
There is a spectrum of well-described toxic effects of tacrolimus.  The primary toxicities in large, 
controlled trials were reversible renal insufficiency (doubling of creatinine in 82%), hypertension 
requiring the use of antihypertensive medications (21%), hyperglycemia (12%), 
hypomagnesemia, hypokalemia, and neurologic toxicity.  In addition there is an infusional 
toxicity from the cremaphor diluent.  There is an increased risk of opportunistic infections and 
secondary malignancies.  Some of these toxicities are recognized complications of 
transplantation.  
 
[IP_ADDRESS].  Methotrexate 
 The most frequently reported adverse reactions associated with methotrexate use as GVHD 
prophylaxis include ulcerative stomatitis, leucopenia and suppressed hematopoiesis, nausea, and 
abdominal distress.  Other frequently reported adverse effects are malaise, undue fatigue, chills 
and fever, dizziness and decreased resistance to infection.  Methotrexate may be associated with 
increased rates of pulmonary complications after transplantation.  The risk of infections is due to 
the suppression of hematopoiesis after transplantation.  
 
2.8.3.  Drug Interactions 
 
[IP_ADDRESS].  Sirolimus 
 
Sirolimus is known to be a substrate for both cytochrome CYP3A4 and P-glycoprotein. 
 
Drugs that may increase sirolimus blood concentrations include:  
 Calc
ium channel blockers: diltiazem, nicardipi[INVESTIGATOR_050], verapamil.  
 Calc
ineurin inhibitors: cyclosporine. 
 Ant
ifungal agents: ketoconazole, clotrimazole, fluconazole, itraconazole.  
 Mac
rolide antibiotics: clarithromycin, erythromycin, troleandomycin.  
 Gast
rointestinal prokinetic agents: cisapride, metoclopramide.  
 Other 
drugs: rifampin, bromocriptine, cimetidine, danazol, HIV-protease inhibitors (e.g., 
ritonavir, indinavir).  
 
Due to extreme interactions with voriconazole, this drug is contraindicated during 
sirolimus therapy.  It is recommended that drugs with known interactions with sirolimus 
be avoided when clinically feasible.  When these medications are required, dose 
modifications of sirolimus may be required.  For guidelines on the simultaneous use of 
sirolimus and oral voriconazole, see Appendix H. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-1
5 Dru
gs that may decrease sirolimus concentrations include: 
 Ant
iconvulsants: carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin. 
 Ant
ibiotics: rifabutin, rifapentine.  
 He
rbal preparations: St. John's Wort ( Hypericum perforatum ) could result in reduced 
sirolimus concentrations.  
 
Care should be exercised when drugs or other substances that are metabolized by [CONTACT_097]3A4 are 
administered concomitantly with sirolimus.  Grapefruit juice reduces CYP3A4-mediated 
metabolism of sirolimus and must not be used for dilution. 
 
[IP_ADDRESS].  Tacrolimus 
 
Tacrolimus is extensively metabolized by [CONTACT_35233] P-450 (CYP3A4) system.  
  
Drugs that may increase tacrolimus blood concentrations include:   
 Calc
ium channel blockers: diltiazem, nicardipi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], verapamil 
 Ant
ifungal agents: ketoconazole, clotrimazole, fluconazole, itraconazole 
 Mac
rolide antibiotics: clarithromycin, erythromycin, troleandomycin.  
 Gast
rointestinal prokinetic agents: cisapride, metoclopramide.  
 Other 
drugs: bromocriptine, cimetidine, cyclosporine, danazol, ethinyl estradiol, 
omeprazole, nefazodone, HIV-protease inhibitors (e.g., ritonavir, indinavir).  
 Drugs that may decrease tacrolimus concentrations include: 
 Ant
iconvulsants: carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin. 
 Ant
ibiotics: rifabutin, rifapentine.  
 He
rbal preparations: St. John's Wort (hypericum perforatum ) could result in reduced 
tacrolimus concentrations.  
 
Due to extreme interactions with voriconazole, tacrolimus doses should be empi[INVESTIGATOR_501763] 50% when concomitant therapy with voriconazole is initiated.  It is 
recommended that drugs with known interactions with tacrolimus be avoided when 
clinically feasible.  When these medications are required, dose modifications of tacrolimus 
may be required. 
 
[IP_ADDRESS].  Methotrexate 
 
Methotrexate is partially bound to serum albumin, and toxicity may be increased because of 
displacement by [CONTACT_115143], such as salicylates, phenylbutazone, phenytoin, and sulfonamides.  
Renal tubular transport is also diminished by [CONTACT_115144]; use of methotrexate with this drug 
should be carefully monitored. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646499]-spectrum 
antibiotics, may decrease intestinal absorption of methotrexate or interfere with the enterohepatic 
circulation by [CONTACT_115145]. 
Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of 
methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed 
with high and low dose methotrexate. Use of methotrexate with penicillins should be carefully 
monitored.  
 
2.9. Management of Toxicities 
 
Toxicities will be scored as per the NCI’s Common Terminology Criteria for Adverse Events 
(CTCAE) version 3.0 (see http://ctep.cancer.gov/forms/CTCAEv3.pdf).  Toxicities of the 
blood/bone marrow, gut, liver, and skin will be excluded from the common toxicity criteria and 
evaluated separately since they are likely to be affected by [CONTACT_93124].  GVHD severity will be 
determined clinically, however, biopsies of affected organs are strongly encouraged whenever 
possible.  
 
2.9.1.  GVHD 
 
Specific therapy of GVHD will not be mandated by [CONTACT_990], although it is recommended that 
only Grade II-IV GVHD be treated with systemic therapy.  A recommendation for initial therapy 
of GVHD is methylprednisolone, 2 mg/kg/d IV (or an equivalent corticosteroid).  If the patient 
responds to steroids, the steroid will be tapered as tolerated clinically, but with the intent of 
decreasing the dose by 10%/week.  For steroid non-responders, treatment for GVHD will be per 
local institutional standards.  Tacrolimus and sirolimus (in the appropriate treatment group) 
should be continued during treatment of acute GVHD. 
 
Whenever possible, the diagnosis of GVHD should be confirmed with a biopsy of the involved 
organ and histological examination of a biopsy specimen by a pathologist experienced in the 
diagnosis of GVHD.  Due to the early engraftment anticipated with the omission of methotrexate 
in the sirolimus arm, conditioning-related diarrhea may coincide with engraftment, therefore, 
sigmoidoscopy and biopsy are strongly encouraged to diagnose GVHD of the intestine.  
Diagnosis of isolated hepatic GVHD must be made by [CONTACT_145139]. 
 
2.9.2.  VOD 
 
Treatment of veno-occlusive disease of the liver will be treated per local institutional standards.  
Participation in clinical trials is permissible.  Tacrolimus and sirolimus (in the appropriate 
treatment group) should be continued during VOD therapy.  Levels should be measured 
frequently in the context of hepatic and/or renal failure. 
 
2.9.3.  Idiopathic Pneumonia Syndrome/Diffuse Alveolar Hemorrhage 
 
Treatment of idiopathic pneumonia syndrome/diffuse alveolar hemorrhage will be treated per 
local institutional standards.  Participation in clinical trials is permissible.  Tacrolimus and 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-1
7 s
irolimus (in the appropriate treatment group) should be continued during idiopathic pneumonia 
syndrome/diffuse alveolar hemorrhage therapy.   
 
2.9.4.  Thrombotic Microangiopathy 
 
Thrombotic microangiopathy will be defined according to BMT CTN guidelines.  The diagnostic 
criteria include the concurrent occurrence of: 
1- Red cell fragmentation on a manual differential (2 + schistocytes) with a negative 
Coombs test 
and 
2- LDH > normal 
and either 
3- Renal dysfunction (doubling of serum creatinine or a decrease > 50% in the measured 
creatinine clearance) 
or 
Neurological dysfunction unexplained by [CONTACT_501808].  
Tacrolimus should be discontinued from the GVHD regimen.  At the treating physician’s 
discretion, Mycophenolate Mofetil can be substituted for GVHD prophylaxis.  Sirolimus should 
be held if serum levels are supratherapeutic and restarted once in the target range at an 
appropriate dose.  The use of plasmapheresis and plasma exchange does not appear to be of 
significant clinical utility in the management of transplant-associated microangiopathy, but may 
be used at the discretion of the treating physician.  
 
2.9.5.  Hyperlipi[INVESTIGATOR_501764] a result of prolonged exposure to sirolimus will 
be managed with dietary manipulations and HMG CoA inhibitors or other standard therapy as 
necessary to reduce levels to the normal range.  Study drugs should be continued during therapy 
for hypercholesterolemia and hypertriglyceridemia unless the lipid levels are uncontrollable with 
standard therapy and are deemed to be a risk to the subject, per the treating physician. 
 
2.9.6.  Non-Engraftment 
 
Engraftment will be considered to be three consecutive measurements ANC >  5
00mcL over 
three or more days. If the ANC < 100 on Day 28, evaluation for graft failure will be initiated, 
including bone marrow aspi[INVESTIGATOR_1516]/biopsy, cytogenetics and/or fluorescence in situ hybridization 
(FISH) if appropriate, and RFLP analysis if appropriate.  Plans for a second stem cell infusion 
will be made depending on the results of the work-up. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
2-1
8 2.9
.7. Other Toxicities 
 
All other associated toxicities that may be attributable to sirolimus will be managed 
symptomatically.  If that is unsuccessful and the toxicity can be attributed to sirolimus, this drug 
will be discontinued. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646500] of either of two events:  the development of Grade II-IV GVHD or death from any cause 
prior to 114 days from randomization.  
 3.2. Secondary Endpoints 
 3.2.1.  Neutrophil and Platelet Engraftment 
 
Neutrophil engraftment is defined as achieving an Absolute Neutrophil Count (ANC) > 500/mcL 
for three consecutive measurements on different days.  The first of the three days will be 
designated the day of neutrophil engraftment.  The ANC is calculated by [CONTACT_51632]: 
 
ANC = Total WBC x (%Neutrophils + %Bands) 
 Platelet engraftment is defined as a platelet count > 20,000/mcL for three consecutive 
measurements over three or more days.  The first of the three days will be designated the day of 
platelet engraftment.  Subjects must not have had platelet transfusions during the preceding 3 
days or in the following 7 days after the day of engraftment, unless the platelet transfusion is 
being given specifically to achieve a platelet threshold to allow an elective invasive procedure, 
such as a central catheter removal.  The time to a platelet count > 100,000/mcL will be collected 
as well. 
 
This endpoint will be evaluated through [ADDRESS_646501] non-engraftment.  
 
3.2.2.  Acute GVHD of Grades III-IV 
 
Acute GVHD is graded according to the BMT CTN MOP (see Appendix E).  The first day of 
acute GVHD onset at a certain grade will be used to calculate cumulative incidence curves for 
that GVHD grade (e.g., if the onset of Grade I acute GVHD is on Day [ADDRESS_646502]-transplant, time to Grade III is Day 70).  This endpoint will 
be evaluated through [ADDRESS_646503]-randomization. 
 
3.2.3.  Mucositis Severity 
 
Mucositis severity will be scored per the modified OMAS scoring system (see Appendix F).  
Mucositis scores will be recorded three times per week (Monday, Wednesday and Friday) from 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646504] Hospi[INVESTIGATOR_501765] (Day 0) to the date of first hospi[INVESTIGATOR_501766].  Patients remaining in the hospi[INVESTIGATOR_52965] 100 
will be censored for this outcome. 
 
3.2.5.  Infections 
 
Microbiologically documented infections will be reported by [CONTACT_4622], date of onset, 
severity and resolution, if any.  For definitions, see the BMT CTN MOP. 
 
3.2.6.  CMV Reactivation  
 
CMV reactivation is defined as the presence of viral DNA level  2 pg/mL on two consecutive 
measurements using a viral hybrid capture or other suitable measurement technique.  
 
3.2.7.  Thrombotic Microangiopathy 
 The occurrence of thrombotic microangiopathy (according to the definition in Section 2.9.4) within the first [ADDRESS_646505] day of onset 
will be used for reporting purposes.  The incidence of TMA will be compared between study 
groups using cumulative incidence curves.  
 
3.2.8.  VOD 
 
VOD will be defined as the occurrence of VOD (based on the Baltimore Criteria for the 
diagnosis of VOD) in conjunction with other end-organ dysfunction. 
 
Baltimore Criteria for the Diagnosis of VOD:
 
Jau
ndice (bilirubin ≥ 2 mg/dL) 
and at least 2 of the following 3 clinical findings: 
• Ascites 
• Weight gain ≥ 5% above baseline weight (defined as weight on the first day of conditioning or the weight on the date of admission) 
• Hepatomegaly (with pre-existing hepatomegaly there must be documentation by 
[CONTACT_501809]) 
 
Severe VOD is defined as meeting the above criteria and also demonstrating multi-organ failure, 
i.e., presence of one or both of the following: 
• Renal dysfunction: 
• Serum creatinine ≥ 3 x value on the date of admission or ≥ [ADDRESS_646506] (whichever is lowest) 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
3-3 • Cre
atinine clearance or GFR ≤ 40% of admission value 
• Dialysis dependence 
• Pulmonary dysfunction:  
• Documentation of oxygen saturation ≤ 90% on room air or requirement for oxygen supplementation/ventilator dependence. Dysfunction must be attributable 
to fluid overload or mechanical impi[INVESTIGATOR_501767] 
 
3.2.9.  Chronic GVHD 
 
Chronic GVHD is scored according to the BMT CTN MOP.  The first day of chronic GVHD 
onset will be used to calculate cumulative incidence curves. 
 
3.2.10.  Relapse of the Original Malignancy 
 Relapse of Malignancy
 - T
esting for recurrent malignancy in the blood, marrow or other sites 
will be used to assess relapse after transplantation.  For the purpose of this study, relapse is 
defined by [CONTACT_501810], ALL, CML, MDS or CMML 
consistent with pre-transplant features.   
 
Minimal Residual Disease  - Mini
mal residual disease is defined by [CONTACT_207125], or fluorescent in situ hybridization (FISH), or Southern blot, 
or Western blot, or polymerase chain reaction (PCR), or other techniques, in absence of 
morphological or cytogenetic evidence of disease in blood or marrow.  Since the frequency of 
testing for minimal residual disease is highly variable among centers, and the sensitivity is highly 
variable among laboratory techniques, evidence of minimal residual disease will not be sufficient 
to meet the definition of relapse in the context of this study, even if transplant physicians will 
utilize the information to alter therapy.  Data on tapering immunosuppression, infusing donor T 
cells, administering chemotherapy or biological agents to attempt reducing the tumor load will be 
captured in the case report forms. 
 
Acute Leukemia  - R
elapse will be diagnosed when: 
1. Leukemic blasts (> 25%) are documented in the blood or bone marrow after 
transplantation, or  
2. Leukemic blasts > 5% and <  25
% are documented in the blood or bone marrow and 
supported by [CONTACT_501811], or  
3. Leukemic blasts > 5% and <  25
% are documented in the blood or bone marrow on at 
least 2 occasions, or  
4. There is leukemia detected at an extramedullary site.  
 
Chronic Myelogenous Leukemia  - R
elapse will be diagnosed when:  
1. Immature hematopoietic cells are persistently documented in the peripheral blood, or  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
3-4 2. T
here is myeloid hyperplasia in the bone marrow in the presence of a cytogenetic relapse, 
as defined by: 
a) 50% of the metaphases exhibit the characteristic 9;[ADDRESS_646507] ten 
metaphases analyzed, or 
b) At least one metaphase exhibits the 9;[ADDRESS_646508] one month apart, regardless of number of 
metaphases analyzed. 
Myelodysplastic Syndrome
 - Relap
se will be diagnosed when: 
1. Reappearance of pre-transplant morphologic abnormalities, detected in two consecutive 
bone marrow specimens taken at least one month apart, or 
2. Satisfying above criteria for evolution into acute leukemia, or   
3. Reappearance of pre-transplant cytogenetic abnormalities in at least 50% of metaphases 
with at least ten metaphases examined, or 
4. Reappearance of pre-transplant cytogenetic abnormality in at least two metaphases on 
each of two separate consecutive examinations at least one month apart, regardless of the 
number of metaphases analyzed. 
 
3.2.11.  Survival  
 
Both overall survival and relapse-free survival will be assessed one and two years from the time 
of randomization.  All patients will be assessed in an intention-to-treat fashion.  Patients alive at 
the time of last observation will be censored. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010  
 
 
4-1 CH
APTER 4 
 
 
4. PATIENT 
REGISTRATION, RANDOMIZATION AND ENROLLMENT 
 
4.1. Approaching Patients, Eligibility Screening and Obtaining Consent 
 
Subjects will be approached for this study after the decision to proceed with transplantation is 
made and a suitable HLA-matched sibling identified.  Transplant physicians will evaluate the 
patient eligibility for randomization onto this study (see Section 2.3).  Eligibility criteria will be 
verified and ineligible patients will proceed off study and no further follow-up will be obtained 
Eligible patients willing to participate in the trial will sign an Institutional Review Board (IRB) 
approved consent form.  Transplant center personnel will record the documentation of patient 
consent in EMMES AdvantageEDCS
M (
Electronic Data Capture, an Internet-based data entry 
system) and patients will be registered through AdvantageEDC. 
 
4.2. Transplant Protocol Registration 
 
Before randomization occurs, the transplant center must state through AdvantageEDC which 
conditioning regimen will be used for the enrolled subject.  Such a registration step will avoid 
potential biases that preferential use of a certain regimen on one treatment arm could confer to 
the study.  At this stage, the transplant center will also verify that the patient is still a candidate 
for transplantation, and eligible for the trial. 
 
4.3. Randomization 
 Once the subject is deemed eligible and has given written informed consent, and the transplant 
center has confirmed patient eligibility and registered the patient’s conditioning regimen, 
randomization occurs.  Randomization should occur within [ADDRESS_646509] be completed within six weeks of conditioning for 
transplantation.  This step is necessary because patient organ function, infection status and status 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646510] patients with a new 
contraindication to transplant from initiating transplant therapy at an unsafe time. 
 
4.6. Study Monitoring 
 
A visit schedule based on transplant date is displayed for printing in AdvantageEDC and is 
shown in Table 4.6a. 
 
Table 4.6a – Follow-Up Schedule 
 
Study Visit Target Day Post-Transplant  
Basel
ine  28
 days from conditioning 
1 we
ek 7  2 da
ys 
2 we
ek 14  2 days 
3 we
ek 21  2 days 
4 we
ek 28  2 days 
5 we
ek 35  2 days 
6 we
ek 42  2 days 
7 we
ek 49  2 days 
8 we
ek 56  2 days 
9 we
ek 63  2 days 
10
 week 70  2 days 
12
 week 84  2 days 
10
0 day 100  5 days 
6 month 18
0  14
 days 
9 month 27
0   d
ays 
12
 month 365  14
 days 
24
 month 730  28
 days 
 
4.6
.1. Patient Assessments 
 
Table 4.6b summarizes patient clinical assessments over the course of the study. 
BMT CLINICA
L TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
4-3 Table
 4.6b – Patient Clinical Assessments 
 
Study Assessments/  
Testing  Base
lin
e Day
s Post-Transplant  
7 1
4 2
1 2
8 3
5 4
2 4
9 5
6 6
3 7
0 7
7 8
4 9
1 9
8 1
00 1
80 2
70 3
65 7
30 
His
tory, Physical Exam, 
Weight, Height, Karnofsky/ 
Lansky Performance Status X X X X X X X X X X X  X   X X X X X 
CBC1, 
Differential, Platelet 
Count, Blood Chemistries2 X X X X X X X X X X X  X   X X X X X 
I
nfectious Disease Titers3 X                    
Seru
m Cholesterol and 
Triglyceride Levels X    X    X       X X X X X 
EKG
, PFT, Chest X-ray X                    
Bon
e Marrow Aspi[INVESTIGATOR_501768] X               X   X X 
ß-HCG S
erum Pregnancy 
Test (females only) X                    
Siro
limus/Tacrolimus Level4  X X X X X X X X X X  X   X X X X X 
M
ucositis Score5  X X X                 
GV
HD and Toxicity 
Assessments6  X X X X X X X X X X X X X X X X X X X 
Imm
une Reconstitution 
Assays     X           X X  X X 
Wh
ole Blood Sample7  X    X           X X  X XX 
1 CB
C performed three times weekly from Day 0 until ANC > 500/mcL for three days and platelet count > 20,000/mcL after nadir, while hospi[INVESTIGATOR_057].  CBC then performed weekly 
through [ADDRESS_646511]-transplant. 
2 Bl
ood chemistries include: creatinine, bilirubin, alkaline phosphatase, AST, and ALT.  Blood chemistries performed twice weekly until Day 28. Blood chemistries performed weekly 
after Day [ADDRESS_646512]-transplant. 
3 I
nfectious disease titers include: CMV, hepatitis panel (HepB SAb, HepB SAg, HepB Core Ab, HepC Ab), herpes simplex virus, varicella zoster virus, syphilis, HIV and HTLV ½ 
antibody. 
[ADDRESS_646513]-transplant.  GVHD assessments performed weekly until Day 98. 
7 Sam
ple amount of 16 
mL, or 8mL for patients < 12 years old.  To be cryopreserved at the transplant center for future testing.  The center may make further adjustments in 
blood volumes collected from patients less than 12 years old to meet the institution’s Human Investigational Committee’s Guidelines. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
4-4 4.6
.1.1. Pre-transplant evaluations 
 
The following observations should be made < six weeks before initiation of conditioning 
therapy : 
1. History, physical examination, height and weight. 
2. Karnofsky/Lansky performance status. 
3. CBC with differential and platelet count, creatinine, bilirubin, alkaline phosphatase, AST, 
ALT. 
4. CMV antibody test, hepatitis panel (HepB SAb, HepB SAg, HepB Core Ab, HepC Ab), herpes simplex virus, varicella zoster virus, syphilis, HIV and HTLV1/[ADDRESS_646514] X-ray. 
10. -HCG for serum pregnancy test (females only). 
11. Blood (16 mL, or 8 mL for patients < 12 years old) from recipi[INVESTIGATOR_501769].  This should be collected and 
processed per Appendix C.  The center may make further adjustments in blood volumes 
collected from patients less than 12 years old to meet the institution’s Human 
Investigational Committee’s Guidelines. 
12. Blood (16 mL, or 8 mL for patients < 12 years old) from donor to be cryopreserved at the 
transplant center for genetic testing if consent obtained.  This should be collected and processed per Appendix C.  The center may make further adjustments in blood volumes 
collected from patients less than 12 years old to meet the institution’s Human 
Investigational Committee’s Guidelines. 
 
[IP_ADDRESS].  Post-transplant evaluations 
 
The following observations should be made according to Table 4.6b: 
1. History and physical exam to assess GVHD and other morbidity weekly through Day [ADDRESS_646515] three times a week from Day 0 until ANC > 500/mcL for 3 days and platelet 
count > 20,000/mcL for 3 days (while hospi[INVESTIGATOR_381257]) after nadir reached.  A manual 
differential must be performed.  Thereafter CBC weekly until [ADDRESS_646516]-transplant. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646517]-
transplant (only when subject is using the medication). 
6. Mucositis assessment three times per week (Monday, Wednesday and Friday) while 
hospi[INVESTIGATOR_501770] 21 (see Appendix F for modified OMAS scoring system). 
7. Serum cholesterol and triglyceride level at months [ADDRESS_646518]-transplant. 
9. Immune reconstitution blood samples at Days 28, 100, 180, 365 and 730 (see Appendix 
C). 
10. Investigational future testing blood samples (16 mL, or 8 mL for patients < 12 years old) at Days 28, 100, 180, 365 and 730 if consent obtained (see Appendix C).  The center may make further adjustments in blood volumes collected from patients less than 12 years old 
to meet the institution’s Human Investigational Committee’s Guidelines. 
 
4.6.2.  Case Report Forms 
 
A description of the forms, the procedures required for forms completion and timeliness of 
submission can be found in the Data Management Handbook and User’s Guide.  Forms that are 
not received within the specified time are considered delinquent.  Transplant centers can view 
submitted past due, and expected forms via AdvantageEDC.  A missing form will continue to be 
requested either until the form is reported, or until an exception is granted. 
 
4.6.3.  Reporting Patient Deaths 
 Recipi[INVESTIGATOR_501771] (DCC) 
within one business day of the event.  Death after the patient has left the transplant center must 
be reported within one business day of the event notification to the transplant center. If the cause 
of death is unknown, it need not be recorded at the time of initial reporting.  However, once the 
cause of death is determined, the form must be updated. 
 
4.6.4.  Reporting Serious Adverse Events 
 
[IP_ADDRESS].  Patient SAEs 
 
Reporting of patient serious adverse events (SAE) will be consistent with standard BMT CTN 
procedures.  Unexpected, grades 3-5 adverse events (AEs) will be reported through an expedited 
AE reporting system via the web-based electronic data capture system, AdvantageEDC.  
Unexpected, grades 4-5AEs must be reported within 24 hours of knowledge of the event.  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646519] be reported within three business days of knowledge of the event.  
Other SAEs will be tracked periodically as defined in the Form Submission Schedule, staged 
according to NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0.  
The Data and Safety Monitoring Board will receive summary reports of all adverse experiences 
on at least an annual basis. 
 
4.6.5.  CIBMTR Data Reporting 
 
All transplant centers will be required to pre-register patients with the Center for International 
Blood and Marrow Transplant Research (CIBMTR) for all transplant patients whether or not 
they enroll in a BMT CTN Protocol.  In addition, the transplant center must complete the 
CIBMTR Day 100 Report Form (including the Core, Graft and Disease Inserts) and CIBMTR 
Follow-up Form (including the Core and Disease Inserts) yearly for all patients enrolled in BMT 
CTN protocols.  CIBMTR forms will be submitted directly to the CIBMTR at the times specified 
on the Form Submission Schedule. 
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646520]
ATISTICAL CONSIDERATIONS 
 
5.1. Study Design 
 
The study is designed as a Phase III, randomized, open label, multicenter, prospective 
comparative study of sirolimus and tacrolimus versus tacrolimus and methotrexate as GVHD 
prophylaxis after HLA-matched, related peripheral blood stem cell transplantation in patients 
with hematologic malignancies.  The target enrollment is 312 patients. 
 
5.1.1.  Accrual 
 
It is estimated that three years of accrual will be necessary to enroll the targeted sample size.  
Both Core and non-Core Centers will enroll patients on this study.  Accrual will be reported by 
[CONTACT_545], ethnicity, gender, and age (pediatric patients will be defined as < 18 years). 
 
5.1.2.  Randomization 
 
All patients will be randomized within 7 days prior to the initiation of conditioning therapy.  
Randomization will be performed in a 1:[ADDRESS_646521]-randomization will be considered events for this endpoint. 
 
5.1.4.  Primary Hypothesis 
 
The primary null hypothesis of the study is that there is no difference between the GVHD-free 
survival rates for sirolimus and tacrolimus compared to tacrolimus and methotrexate. 
 
H
o: pst = p t
m 
Ha: pst  pt
m 
 
5.[ADDRESS_646522] been 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646523] will be used in the event of loss to follow 
up as well as in the interim analyses conducted with incomplete follow-up.  The sample size of 
156 patients per group is sufficient to maintain type I error of 5% across all planned interim 
analyses (see below) while providing 80% statistical power for a two-sided test to detect an 
increase in the proportion surviving without Grade II-IV GVHD at 114 days from 0.60 in the 
tacrolimus/methotrexate arm to 0.75 in the sirolimus/tacrolimus arm.   
 
5.3. Interim Analysis and Stoppi[INVESTIGATOR_501772]-appointed Data and Safety Monitoring Board (DSMB) at approximately 
six month intervals.  Monitoring of key safety endpoints will be conducted monthly, and if rates 
significantly exceed pre-set thresholds, the NHLBI will be notified in order that the DSMB can 
be advised.  Policies and composition of the DSMB are described in the BMT CTN's Manual of 
Procedures. 
 
5.3.1.  Interim Analysis for Efficacy 
 
Analyses will be performed as described below for the primary endpoint.  Toxicity, adverse 
events, and other safety endpoints will be monitored regularly and reported to the DSMB at each 
interim analysis.  
 
At the time of each interim analysis, the test statistic based on the Kaplan-Meier proportion will 
be compared to the critical value shown below.  All patients randomized prior to the time of the 
interim analyses will be used to compute the Kaplan-Meier estimate.  If the test statistic exceeds 
the critical value, the DSMB will discuss the continuation of the trial. 
 
At each interim analysis time point, a two-sided test to detect either an increase or decrease in the 
proportion of patients surviving without Grade II-IV GVHD at 114 days will be performed, as 
described above for the final analysis.  In order to preserve the over-all type I error rate at 5%, 
the critical value for the test statistic will be inflated above 1.96, the value that would be used if 
no repeated testing were used.  Equivalently, the nominal p-value at which an observed 
difference is declared significant will be reduced below 0.05.  The actual critical values and 
nominal p-values will be computed using statistical methods for group sequential testing with 
O’Brien Fleming boundaries.   
 
As an example, Table 5.3a shows the critical values and nominal p-values for tests conducted 
every six months starting with the 9th mon
th after the study opens to enrollment.  The column 
labeled “followed to 114 days” shows the expected number of individuals who have reached the 
114-day post-randomization follow-up time point, assuming uniform accrual over a three-year 
period.  The fraction of patients followed to 114 days, as compared to a denominator comprised 
of the total sample of 312, quantifies the “statistical information” from which the critical values, 
nominal type I errors and cumulative type I error are computed.   
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
5-3  
Ta
ble 5.3a – Critical Values and Cumulative Type I Error 
 
Ca
lendar 
Tim
e 
(Months) Followed to 114 
Days Critical 
Value Nominal Type I 
Error Cumulative Type I 
Error 
9 46 5.0
29 .0000 .0000 
15 98 3.5
56 .0004 .0004 
21 150 2.
903 .0034 .0038 
27 202 2.5
14 .0094 .0132 
33 254 2.2
49 .0158 .0290 
39.
3 (Final) 312 2.053 .0210 .0500 
 
In
 practice, the rate of accrual or timing of DSMB meetings may not be as anticipated.  To 
permit necessary flexibility in scheduling interim analyses, the critical values will be recomputed 
to correspond to the actual available statistical information using the “use-function” approach of 
Lan and DeMets. 
 
5.3.2.  Operating Characteristics of the Design  
 Under the assumption that time to GVHD or death is exponentially distributed, the statistical 
power to reject the null hypothesis of equal 100-day GVHD-free survival is shown in Table 5.3b 
under a variety of scenarios, using the comparison of the Kaplan-Meier estimates.  These 
simulation results assume uniform accrual of patients over three years.  This table shows that the 
target sample size of 312 patients has 80% power to detect a 15% improvement in GVHD-free 
survival. 
 
Table 5.3b – Power to Reject the Null Hypothesis under Various Scenarios 
 
 Proportion 
Survi
ving Pow
er at Interim and Final Analyses  
O
verall  G
VHD -Fre
e at Day [ADDRESS_646524] Exp
eriment  9 15 21 27 33 39.3 Pow
er 
312 .60 .60 .000 .001 .004 .011 .018 .021 .055 
312 .60 .70 .000 .011 .057 .116 .144 .123 .451 
312 .60 .75 .001 .044 .177 .248 .207 .125 .802 
312 .60 .80 .003 .136 .358 .293 .133 .049 .972 
* fr
om simulation with 10,000 replications, assuming exponential time to failure  
  
5.3
.3. Guidelines for Safety Monitoring 
 
The cumulative incidences of thrombotic microangiopathy and severe veno-occlusive disease 
(VOD) at [ADDRESS_646525]-transplant will be monitored separately for each arm.  Death without 
each type of toxicity will be considered as a competing risk for that event.  Refer to Section 3.2 
for definitions of these safety monitoring endpoints.  Monitoring will be performed monthly until 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
5-4 e
nrollment to that treatment arm is closed.  Each month, the null hypothesis that the cumulative 
incidence of thrombotic microangiopathy is less than or equal to 10% will be tested against the 
alternative that it is greater than 10%.  Similarly, the cumulative incidence of severe VOD will 
be tested against a null value of 10%.  Since the busulfan/cyclophosphamide conditioning 
regimen was removed early in the study due to toxicity, only patients who receive TBI-based 
conditioning regimens will be included in the safety monitoring analysis for severe VOD. 
 
A truncated Sequential Probability Ratio Test (SPRT) for a binomial outcome will be used for 
each endpoint, as described in greater detail below.  Note that in the absence of censoring, the 
binomial proportion of patients experiencing the toxicity prior to death is equal to the cumulative 
incidence. This sequential testing procedure conserves type I error across all of the monthly 
examinations for a single toxicity endpoint, but not across the multiple safety endpoints or two 
treatment arms.  Thus for a single endpoint and study arm, the type I error is approximately 5%, 
and across both safety endpoints and both treatment arms, the study-wise type I error is < 20%. 
 
The rationale for not conserving type I error across multiple safety endpoints and treatments is 
twofold.  First, adjusting the size of the test for multiple comparisons would reduce statistical 
power to detect adverse outcomes, which seems imprudent.  Secondly, the procedure is a 
guideline for requiring additional review by [CONTACT_39109], and is not a 
formal “stoppi[INVESTIGATOR_1877]” that would mandate automatic closure of study enrollment.   
 
The SPRT can be represented graphically.  At each monthly interim analysis, the total number of 
patients enrolled is plotted against the total number of endpoints observed in those patients, (e.g., 
patients with thrombotic microangiopathy).  The continuation region of the SPRT is defined by 
[CONTACT_110893].  Only the upper boundary will be used for monitoring each treatment arm to 
protect against poor 100-day incidences of rates of thrombotic microangiopathy.  If the graph 
falls above the upper boundary, the SPRT rejects the null hypothesis, and concludes that there 
are more events of thrombotic microangiopathy than predicted by [CONTACT_501812].  Otherwise, the SPRT continues until enrollment to the treatment arm 
reaches the target goal.   
 
The usual measures of performance of an SPRT are the error probabilities  and  of rejecting 
H0 wh
en  = 0 an
d of accepting H 1 w
hen  = 1,
 r
espectively, and the expected sample size 
E(N|i).  T
he tests to be used in this protocol were developed from the following SPRTs:   
 
 A SPRT contrasting 10% versus 20% 100-day cumulative incidence of thrombotic 
microangiopathy, with nominal type I and II errors of 5.5% and 20%, respectively.  The 
common slope of the parallel lines is 0.145 and the intercept for the upper boundary is 
3.301. 
 A SPRT contrasting 10% versus 20% 100-day cumulative incidence of severe VOD, with 
nominal type I and II errors of 5.5% and 20%, respectively.  The common slope of the 
parallel lines is 0.145 and the intercept for the upper boundary is 3.301. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646526] will be slightly lower than the nominal level of 5.5% and closer to 5%.  
 
Table 5.3c demonstrates the stoppi[INVESTIGATOR_98350]. 
 
Table 5.3c – Sample Stoppi[INVESTIGATOR_501773], n Stop if Number of 
Events in First n 
Patients is >= x Number of Patients 
Enrolled, n Stop if Number of 
Events in First n 
Patients is >=x 
15 6 90 17 
30 8 10
5 19 
45 10 12
0 21 
60 13 13
5 23 
75 15 15
0 26 
 Note 
that because there is a lag from transplant to complete follow up (100 days), the stoppi[INVESTIGATOR_501774].  For example, there may be [ADDRESS_646527] or the competing event of death prior to observing that toxicity.  The monitoring 
rule is based only on the binomial outcome of whether a patient experienced the toxicity by 100 
days and prior to death.  Because the simulations only use a binomial outcome, the mean month 
stopped is calculated based on the accrual time of the patient triggering the stoppi[INVESTIGATOR_1877] + 100 
days for complete follow up.  In practice, because of the potential for the stoppi[INVESTIGATOR_98353] a particular patient, the actual mean month stopped may 
be earlier than shown in the simulation results.  However, this is difficult to estimate because it is 
dependent on assumptions about the time to event distribution for both the toxicity event and the competing risk, as well as the dependence between them.   
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
5-6 Ta
ble 5.3d – Operating Characteristics of Sequential Testing Procedure 
 from a Simulation Study with 10,000 Replications 
 
Throm
botic Microangiopathy 
True 100-Day Rate 10% 15% 20% 
Prob
ability Reject Null 0.052 0.484 0.934 
Me
an Month Stopped 38.1 30.3 18.6 
Me
an # Endpoints in 100 Days 15.2 18.1 14.9 
Me
an # Patients Enrolled 151.4 120.3 73.9 
 
 Seve
re VOD 
True 100-Day Rate 10% 15% 20% 
Prob
ability Reject Null 0.052 0.484 0.934 
Me
an Month Stopped 38.1 30.3 18.6 
Me
an # Endpoints in 100 Days 15.2 18.1 14.9 
Me
an # Patients Enrolled 151.4 120.3 73.9 
 
Fo
r example, the testing procedure for thrombotic microangiopathy rejects the null hypothesis in 
favor of the alternative 5% of the time when the true 100-day incidence is 10%, and 93% of the 
time when the rate is 20%.  When the true 100-day toxicity incidence is 20%, on average, the 
Data and Safety Monitoring Board will be consulted 18.[ADDRESS_646528] been observed in 73.9 patients.   
 5.4. Demographic and Baseline Characteristics 
 
Demographics and baseline characteristics will be summarized for all patients.  Characteristics to 
be examined are: age, gender, race/ethnicity, performance status, primary disease, risk status, 
donor age, donor gender, and donor ethnicity.  Between group comparisons will be performed 
for continuous variables via a t-test and for categorical variables, via the chi-square test. 
 
5.5. Analysis of Secondary Endpoints 
 
1. Time to stable neutrophil and platelet engraftment after transplantation ; cumulative 
incidence curves will be computed by [CONTACT_3148].  A log-rank test will be used to compare 
the two arms.  A Cox proportional hazards model will be fit to control for important 
prognostic variables.  
2. Time to Grades II-IV or Grades III-IV acute GVHD ; cumulative incidence curves 
will be computed by [CONTACT_3148].  A log-rank test will be used to compare the two arms.  A Cox proportional hazards model will be fit to control for important prognostic variables.  
3. Mucositis severity ; median (range) and maximal mucositis scores will be summarized by 
[CONTACT_382620] a Mann-Whitney Wilcoxon test.  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646529] hospi[INVESTIGATOR_2345] ; cumulative incidence curves will be computed by 
[CONTACT_3148].  A log-rank test will be used to compare the two arms.  A Cox proportional 
hazards model will be fit to control for important prognostic variables.  
5. Incidence of infection ; cumulative incidence curves will be computed by [CONTACT_3148].  A 
log-rank test will be used to compare the two arms.  A Cox proportional hazards model will be fit to control for important prognostic variables.  
6. Incidence of CMV reactivation ; cumulative incidence curves will be computed by 
[CONTACT_3148].  A log-rank test will be used to compare the two arms.  A Cox proportional 
hazards model will be fit to control for important prognostic variables.  
7. Incidence of thrombotic microangiopathy ; cumulative incidence curves will be 
computed by [CONTACT_3148].  A log-rank test will be used to compare the two arms.  A Cox 
proportional hazards model will be fit to control for important prognostic variables.  
8. Time to chronic GVHD ; cumulative incidence curves will be computed by [CONTACT_3148].  A 
log-rank test will be used to compare the two arms.  A Cox proportional hazards model will be fit to control for important prognostic variables.  
9. Relapse of primary malignant disease in distinct disease subgroups ; cumulative 
incidence curves will be computed by [CONTACT_3148].  A log-rank test will be used to compare 
the two arms.  Also, a Cox proportional hazards model will be fit to control for important 
prognostic variables.  All patients will be followed for a minimum of one year post-
transplant for relapse.  
10. Relapse-free and overall survival ; Kaplan-Meier curves will be computed by [CONTACT_3148].  
A log-rank test will be used to compare the two arms.  Also, a Cox proportional hazards 
model will be fit to control for important prognostic variables.  All patients will be 
followed for a minimum of one year post-transplant for mortality and relapse.  
Two-sided tests will be used throughout.  A p-value of 0.05 or less will be considered 
statistically significant. 
 5.6. Safety Analysis 
 
All entered patients will be included in the safety analysis: 
1. Serious Adverse Events : All reported serious adverse events potentially associated with 
study drug will be carefully examined with respect to the severity and relationship to study drug.  Adverse events will be graded according to the NCI Common Terminology 
Criteria for Adverse Events Version 3.0.  The incidence for each reported study drug 
associated adverse event delineated in Section 2.8.2 will be presented for each group.  
2. Clinical Laboratory Tests : Laboratory tests will be performed during the study. 
Descriptive statistics will be calculated for each laboratory test.  Abnormal laboratory test results will be summarized in the report.  Laboratory data will be cross-classified into 
below, within, and above the reference range according to their values at screening and 
during the study.  
  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
A-1  
   
APPENDI
X A 
 
SAMPLE TAPERING SCHEDULES 
FOR SIROLIMUS AND TACROLIMUS 
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
A-2 APPEND
IX A  
 
SAMPLE TAP
ERING SCHEDULES FOR SIROLIMUS AND TACROLIMUS  
  
EXAM
PLE 1:  
  St
arting doses: Sirolimus 4 mg qd 
    Tacrolimus 2 mg bid 
 
  Day 100  Sirolimus 3 mg  Tacrolimus  2 mg bid 
  Day 100 + 2 Weeks Sirolimus  3 mg  Tacrolimus  1.5 mg bid 
  Day 100 + 4 Weeks Sirolimus  2 mg  Tacrolimus  1.5 mg bid 
Day 100 + 6 Weeks Sirolimus  2 mg  Tacrolimus  1.0 mg bid  
Day 100 + 8 Weeks Sirolimus  1 mg  Tacrolimus  1.0 mg bid  
Day 100 + 10 Weeks Sirolimus  1 mg  Tacrolimus  0.5 mg bid  
Day 100 + 12 Weeks Sirolimus  0 mg  Tacrolimus  0.5 mg bid  
Day 100 + 14 Weeks Sirolimus  0 mg  Tacrolimus  0 mg bid  
 
EXAMPLE 2:  
  St
arting doses: Sirolimus 2 mg qd 
    Tacrolimus 3 mg bid  
Day 100  Sirolimus 2 mg  Tacrolimus  2.0 mg bid 
  Day 100 + 2 Weeks Sirolimus  1.5 mg  Tacrolimus  2.0 mg bid   Day 100 + 4 Weeks Sirolimus  1.5 mg  Tacrolimus  1.0 mg bid 
Day 100 + 6 Weeks Sirolimus  1 mg  Tacrolimus  1.0 mg bid  
Day 100 + 8 Weeks Sirolimus  1 mg  Tacrolimus  0.5 mg bid  
Day 100 + 10 Weeks Sirolimus  1 mg qod
* T
acrolimus  0.5 mg bid  
Day 100 + 12 Weeks Sirolimus  1 mg qod Tacrolimus  0 mg bid 
Day 100 + 14 Weeks Sirolimus 0 mg  Tacrolimus  0 mg  
 
* [ADDRESS_646530] 
in capsule format.  Caplets may be manually split. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
B-1  
   
APPENDI
X B 
 
INFORMED CONSENTS 
  
 Participant Consent 
 
 Donor Consent 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page [ADDRESS_646531] Information 
(Insert contact [CONTACT_29073] [INVESTIGATOR_29061]) 
  
Study Sponsor: This study is sponsored by [CONTACT_7681] (NIH) by [CONTACT_501813] (BMT 
CTN). 
 
 
Introduction 
This is a clinical trial, which is a research study to answer specific medical questions.  The 
information from this study will help future patients.  The Study doctor (the person in charge of 
the research) will explain the clinical trial to you.  Clinical trials include only people who choose 
to join the study.  
 
Please take your time to decide if you want to join this study.  Some people find it helpful to talk 
about the study with their family and friends before they make a decision.  It may also be useful 
to talk with your doctor and other people on your health care team about the study.  If you have 
questions or want to know more about the study, you can ask them for more information. 
 
You are asked to join this study because: 
1. You have a disease that can be treated by a peripheral blood stem cell transplant; and,  
2. You have a brother or sister who has agreed to be your donor.  
 
Before you decide whether or not to join the study, please read the information below.  Feel free 
to ask questions to understand your rights and protections.  Participating in this study is your 
choice.  If you decide not to be in this study , you and your doctor will discuss other treatment 
options. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 2 of 19 Participant initials ______ Wh
y is this study being done? 
Stem cell transplantation is a standard therapy for acute and chronic leukemias and 
myelodysplastic disorders.  A common problem that may occur after a stem cell transplant is a 
condition known as graft-versus-host disease (GVHD).  The word “graft” refers to the donor 
blood cells that you will receive during your transplant.  The word “host” refers to the person (in 
this case, you) receiving the cells.  GVHD is a complication where the donor graft attacks and 
damages some of your (the transplant recipi[INVESTIGATOR_841]'s) tissues.   
 GVHD can cause skin rash, intestinal problems such as nausea, vomiting, or diarrhea,   
 It may also damage your liver and cause hepatitis or jaundice.   
 GVHD may also increase your risks of infection. 
 
The purpose of this study is to compare two combinations of medications to see which is better 
at preventing GVHD.  These combinations of medications in this study are: 
 A- Sirolimus and tacrolimus  
B- Methotrexate and tacrolimus. 
 
Doctors want to know if combination A is better than combination B or if they give the same 
results.  The study will help doctors make GVHD treatment choices for future transplant patients. 
 
 How many people will take part in the study? 
About [ADDRESS_646532] 
156 patients.   
 
 
What will happen if I take part in this research study? 
Before you begin the study
 -- Y
ou will need to have several exams, tests or procedures to find 
out if you can be in the study.  These exams, tests or procedures are part of regular cancer care 
and may be done even if you do not join the study.  If you have had some of them recently, they 
may not need to be repeated.  This will be up to your doctor with the study. 
 Medical history and physical exam, including height and weight 
 Blood tests  
 Urine tests 
 Heart function tests 
 Lung tests, including a Pulmonary Function Test (PFT) 
 Bone marrow biopsies and aspi[INVESTIGATOR_501775]
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 3 of 19 Participant initials ______  If
 you are a woman able to have children, a pregnancy test will also be performed, using 
a blood sample.  If you are pregnant, you will not be able to take part in this study. 
 
Before your transplant, your doctor will choose from one of two conditioning regimens.  The 
conditioning regimen prepares your body for transplant.  It uses treatments such as chemotherapy 
and radiation to destroy the cancer cells and the cells that make up your immune system.  Your 
doctor will decide which conditioning regimen you will receive before you join one of the study groups.  
 
During the study
 -- I
f the exams, tests and procedures show that you can be in the study, the next 
step is for you to be randomized into one of the study groups described below.  Randomization 
means that you are put into a group by [CONTACT_3364], similar to the flip of a coin.  A computer program 
will place you in one of the study groups.  Neither you nor your doctor can choose the group you 
will be in. 
 
You will begin your conditioning chemotherapy and/or radiotherapy several days prior to the 
transplant.  The treatments to prevent GVHD will begin three days before transplantation for 
both study groups.   
 
A. Sirolimus/tacrolimus group:   
 You 
will take a sirolimus pi[INVESTIGATOR_501776].    
 Tacrolimus will be given by [CONTACT_5204] (through your vein) every day 
while in the hospi[INVESTIGATOR_307].   
 Before you leave the hospi[INVESTIGATOR_501777] a pi[INVESTIGATOR_501778].   
 These medications will be continued for at least 100 days from the time of transplantation.  
 The amount of drug given will slowly be decreased and eventually stopped.  This 
process occurs over several months.  
 
B. Methotrexate/tacrolimus group
:  
 T
acrolimus will be given by [CONTACT_5204] (through your vein) every day 
while in the hospi[INVESTIGATOR_307].   
 Before you leave the hospi[INVESTIGATOR_501777] a pi[INVESTIGATOR_501778].  
 You will take methotrexate on [ADDRESS_646533], 
6t
h a
nd 11th d
ays after your transplant.  
 The tacrolimus will be continued for at least 100 days from the time of 
transplantation.   
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 4 of 19 Participant initials ______  T
he amount of drug given will slowly be decreased and eventually stopped.  This 
process occurs over several months.  
 
Peripheral blood stem cells from your donor will be given to you [ADDRESS_646534]  tests and evaluations: 
 Medical history  
 Physical examination, including height and weight 
 Blood tests  
 Urine tests 
 You will have the following study  tests performed: 
 Blood tests to measure the levels of sirolimus and tacrolimus  
 Blood tests to measure your cholesterol and triglycerides (fat) levels 
 Oral exams to measure any side effects that occur in your mouth and throat 
(mucositis) 
 You will be asked to return to the transplant center for regular follow up care.  The standard tests 
and study tests will be done at that time. 
 
 
How long will I be in the study? 
You will be in the study for up to two years.  You will need to take medication for at least [ADDRESS_646535] of your life by [CONTACT_501814] a year.  Keepi[INVESTIGATOR_501779]-term effects of the study and 
transplantation in general.  Many transplant centers include this type of long-term follow-up as 
part of their regular medical care.  It is not necessary for you to agree to follow-up for longer 
than two years to participate in this study.  
 
 
Can I stop being in the study? 
Yes. You can decide to stop at any time.  Tell your doctor if you are thinking about stoppi[INVESTIGATOR_98358].  He or she will tell you how to stop safely.  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page [ADDRESS_646536] helpful for you. 
 
 
Can the Principal Investigator [INVESTIGATOR_126367]? 
You can be taken off the study (with or without your consent) for any of the following reasons: 
 You do not qualify to be in the study because you do not meet the study requirements.  
Ask your doctor if you would like more information about this. 
 You need a medical treatment not allowed in this study. 
 The investigator decides that continuing in the study would be harmful to you. 
 The study treatments have a bad effect on you. 
 You become pregnant and the study treatment could be harmful to the fetus. 
 You are unable to keep appointments or take study drugs as directed. 
 Other study-specific reasons; for example, if the dose of study drug you are taking has 
been found to be unsafe. 
 The study is cancelled by [CONTACT_2165] (FDA) or the National Institutes of Health (NIH). 
 
 
What side effects or risks can I expect from being in the study?  
Everyone taking part in the study will be watched carefully for any side effects.  However, doctors don't know all the side effects that may happen.  Side effects may be mild or very 
serious.  Your health care team may give you medicines to help lessen side effects.  In some 
cases, side effects can be serious, long lasting, or may never go away.
 
 You 
should talk to your study doctor about any side effects that you have while taking part in the 
study.  
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 6 of 19 Participant initials ______ Pote
ntial Side Effects and Risks from Study Drugs 
Sirolimus and Tacrolimus 
Li
kely (10-25%) Less Likely but Serious (< 10%) 
 Elev
ation of blood lipi[INVESTIGATOR_805] (fats, including 
cholesterol and triglycerides) 
 Mild reduction in blood counts, including 
platelets, red cells (anemia) and white 
blood cells 
 Low blood potassium 
 Muscle aches and pains 
 Fluid retention  
 High blood pressure 
 Tremor  
 Swollen gums  
 Increased facial hair  
  Lung inflammation 
 Reversible kidney damage, which may 
lead to acute kidney failure and require 
hospi[INVESTIGATOR_059], possibly dialysis and 
may lead to permanent kidney failure 
 Thrombotic Microangiopathy, a syndrome 
comprised of abnormal kidney function and destruction of red blood cells and 
platelets.  Temporary dialysis may be 
required for the kidney failure 
 Neurological dysfunction, including a 
decreased level of consciousness, coma, 
blindness and seizures 
 Veno-occlusive disease, which causes 
severe damage to the liver 
 
M
ethotrexate and Tacrolimus 
Li
kely Less Likely but Serious 
 De
lay in the time it takes for your blood 
counts to recover.  This may increase the risk of infection and bleeding after 
transplantation, may increase the 
number of transfusions required during 
the transplantation and may prolong 
your hospi[INVESTIGATOR_4408]. 
 Worsening of mucositis (inflammation 
of the lining of the mouth, throat and 
stomach) 
 Low blood potassium 
 Muscle aches and pains 
 Fluid retention  
 High blood pressure 
 Tremor  
 Swollen gums  
 Increased facial hair  Lung inflammation 
 Reversible kidney damage, which may 
lead to acute kidney failure and require 
hospi[INVESTIGATOR_059], possibly dialysis and 
may lead to permanent kidney failure 
 Thrombotic Microangiopathy, a syndrome 
comprised of kidney dysfunction and 
destruction of red blood cells and 
platelets.  Temporary dialysis may be 
required for the kidney failure 
 Neurological dysfunction, including a 
decreased level of consciousness, coma, 
blindness and seizures 
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page [ADDRESS_646537] combination.  Even though this study is trying to prevent GVHD from 
developi[INVESTIGATOR_007], there is a chance that you will still develop GVHD, no matter which combination 
you receive.  All study participants who develop GVHD will be treated for GVHD.  The 
treatment you receive will be up to your doctor. 
 
Refer to Attachment A for additional risks and toxicities for all transplant patients.  
 
 
A
re there benefits to taking part in the study? 
There may or may not be direct benefits to you from participating in this study.  We hope that 
information gathered in this trial will benefit future transplant patients. 
 
 
What other choices do I have if I do not take part in the study? 
If you do not want to join this study, you should know your other options.  These options 
include: 
 Bone 
marrow transplantation  
 Pe
ripheral Blood Stem Cell Transplantation using standard treatment (but not included in 
study)  
 No 
transplant  
 Other c
hemotherapy  
 No 
therapy for your cancer with care to help you feel comfortable  
 You 
should know about your treatment choices before you decide if you will take part in this 
study. 
 
 
What are the costs of taking part in this study? 
You and/or your insurance company will pay all standard care relating to your stem cell 
transplant.   
 
You will not be billed for any tests or procedures that are only for research.  
 
You will not be paid to be in this study.  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page [ADDRESS_646538] a part in analyzing the results of this study. 
 
For more information on clinical trials and insurance coverage, you can visit the National Cancer 
Institute’s Web site at http://cancer.gov/clinicaltrials/understanding/insurance-coverage . 
 You 
can print a copy of the “Clinical Trials and Insurance Coverage” information from this Web site. 
 
Another way to get the information is to call 1-800-4 -CANCER ([PHONE_1131]) and ask them 
to send you a free copy. 
 
 What if I am injured as a result of being in this study? 
In the event that this research activity results in an injury, treatment will be available including 
first aid, emergency treatment and follow-up care as needed.  Care for such injuries will be billed 
in the ordinary manner, to your insurance company.  If you think you have suffered a research 
related injury, let the study physicians know right away.  Unexpected side effects or accidents 
might result in your getting sicker than anticipated in the course of this treatment.  All available 
medical care will be provided to you, but you and your insurance company (3
rd p
arty payer) are 
responsible for the costs of all such care. If you have any questions about study-related injuries, 
you may contact [insert name [CONTACT_501829]] at [insert phone number]. 
  
What are my rights if I take part in this study?  
Taking part in this study is your choice.  You may choose either to take part or not to take part in 
the study.  If you decide to take part in this study, you may leave the study at any time.  No 
matter what decision you make, there will be no penalty to you and you will not lose any of your 
regular benefits.  Leaving the study will not affect your medical care.  You can still get your 
medical care from our institution.  
 
We will tell you about new information or changes in the study that may affect your health or 
your willingness to continue in the study. 
 
In the case of injury resulting from this study, you do not lose any of your legal rights to seek 
payment by [CONTACT_3368].  
 
If you have questions about your rights as a study subject, you may call the Institutional Review 
Board (IRB) office at [insert phone number]. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 9 of 19 Participant initials ______  
Will
 my medical information be kept private? 
All necessary steps will be undertaken to avoid your being identified in any public presentations.  However, the results of this study treatment may be published in scientific journals in the future, 
but no one patient (including you) will be identified.  Information concerning your transplant 
course may be reviewed or transmitted to national and international transplant registries, 
including the Center for International Blood and Marrow Transplant Research (CIBMTR) and 
the National Marrow Donor Program (NMDP), to the Food and Drug and Administration (FDA), 
Data Coordinating Center of the Blood and Marrow Transplant Clinical Trials Network (BMT 
CTN), the EMMES Corporation (which is helpi[INVESTIGATOR_126368]) and to other 
authorized study organizations.  However, you will not be identified by [CONTACT_501815]. 
 
Information related to or resulting from your stem cell transplant will be reported to the 
CIBMTR.  The CIBMTR is a voluntary organization of basic and clinical scientists working 
together in an effort to gather information on results of stem cell and marrow transplants.  This 
information is used to guide clinical decisions and identify ways to improve transplant outcomes.  
Scientific data or medical information (not identifiable with you) that could be useful to others 
may be presented at meetings and/or published in medical journals. 
 
 
HIPAA
1 aut
horization to use and disclose individual health information for research 
purposes 
 
a. Purpose:  As a research participant, I authorize the Principal Investigator [INVESTIGATOR_126370]’s staff to use and disclose my individual health information for the purpose of 
conducting the research study entitled A Phase III Randomized, Multicenter Trial 
Comparing  Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as GVHD Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation. 
 
b. Individual Health Information to be Used or Disclosed:  My individual health information 
that may be used or disclosed to conduct this research includes: demographic information 
(e.g., age, date of birth, sex, weight), medical history (e.g., diagnosis, complications with 
prior treatment), physical examination findings, and laboratory test results obtained at the 
time of work up and after transplantation (e.g., blood tests, biopsy results).   
 
  
                                                 
[ADDRESS_646539] of 1996, a federal law related to privacy of health 
information  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 10 of 19 Participant initials ______ c
. Parties Who May Disclose My Individual Health Information:  The researcher and the 
researcher’s staff may obtain my individual health information from: 
(list hospi[INVESTIGATOR_600], clinics or providers from which health care information can be requested) 
 
 
 
 
d
. Parties Who May Receive or Use My Individual Health Information:  The individual 
health information disclosed by [CONTACT_29085] c and information disclosed by [CONTACT_334247]: 
 Principal Investigators and the researcher’s staff, including [CONTACT_501834] and 
[CONTACT_501835], Study Chairpersons and staff/laboratories at Dana Farber Cancer 
Institute 
 Staff/laboratories identified in the protocol for the evaluation of other laboratory samples 
 National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer 
Institute (NCI), both of the National Institutes of Health (NIH), study sponsors  
 Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Data and 
Coordinating Center 
 U.S. government agencies that are responsible for overseeing research such as the Food and Drug Administration (FDA) and the Office of Human Research 
Protections (OHRP) 
 U.S. government agencies responsible for overseeing public health concerns such as the Centers for Disease Control (CDC) and federal, state and local health 
departments. 
 Others: 
 
 
 
 
e
. Right to Refuse to Sign this Authorization:  I do not have to sign this Authorization.  If I 
decide not to sign the Authorization, I will not be allowed to participate in this study or 
receive any research-related treatment that is provided through the study.  However, my 
decision not to sign this authorization will not affect any other treatment, payment, or 
enrollment in health plans or eligibility for benefits.   
f. Right to Revoke:   I can change my mind and withdraw this authorization at any time by 
[CONTACT_5583] a written notice to the Principal Investigator [INVESTIGATOR_126371].  If I withdraw this authorization, the researcher may only use and disclose the 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 11 of 19 Participant initials ______ p
rotected health information already collected for this research study.  No further health 
information about me will be collected by [CONTACT_98411]. 
g. Potential for Re-disclosure: My individual health information disclosed under this 
authorization may be subject to re-disclosure outside the research study and no longer 
protected.  Examples include potential disclosures for law enforcement purposes, 
mandated reporting or abuse or neglect, judicial proceedings, health oversight activities 
and public health measures. 
h. DNA from your stored blood sample might be used in genome-wide association (GWA) 
or pharmacogenomics studies for a future project either done or supported by [CONTACT_4878] (NIH).  Genome-wide association studies are a way for 
scientists to identify genes involved in human disease.  This method searches the genome 
for small genetic changes that are more common in people with a particular disease than 
in people without the disease.  Each study can look at hundreds of thousands of genetic 
changes at the same time.  Researchers use data from this type of study to find genes that 
may add to a person’s risk of developi[INVESTIGATOR_007] a certain disease.  Pharmacogenomics studies 
are similar genetic tests but look specifically at genes related to how the body breaks 
down medications.  
i. If your coded samples are used in such a study, the researcher is required to add your test 
results and sample information into a shared, public research database.  This public 
database is called the NIH Genotype and Phenotype Database and it is managed by [CONTACT_501816] (NCBI).  The NCBI will never have any 
information that would identify you, or link you to your information or research samples.  
A new federal law (2009), called the Genetic Information Nondiscrimination Act (GINA) 
generally makes it illegal for health insurance companies, group health plans, and 
employers of [ADDRESS_646540] an expi[INVESTIGATOR_320]. 
 
*****
******************************************* 
Abo
ut Using Blood for Research 
Please note:  This section of the informed consent form is about future research studies that 
will be done using blood samples from people who are taking part in the main study described above.  You may give small blood samples for these future research studies if you want to.  
You can still be a part of the main study even if you say 'no' to giving blood samples for future 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 12 of 19 Participant initials ______ res
earch studies.  You can say "yes" or "no" to giving blood samples for future research 
studies.  Please mark your choice at the end of this section. 
 
We would like to have six small (3 teaspoons or 16 mL) blood samples for future research.  
Patients less than 12 years old will provide 1½ teaspoons or 8 mL).  If you agree, these samples 
will be obtained at the time other blood samples are drawn on 6 occasions pre-transplant and on 
Day 28, 100, 180, 365 and 730.  They will be kept and may be used in research to learn more 
about GVHD, cancer and other diseases.  Usually the blood can be drawn from your central 
venous catheter at the time of the other blood collections.  If this is not possible, it will be taken 
from a vein.  When the sample is given to investigators for research, no information about your 
name, address, phone number or other information that will let the researcher know who you are will be provided. 
 
The samples collected for research purposes will be sent to the National Heart, Lung, and Blood 
Institute (NHLBI) sample repository in Maryland.  The samples will be labeled with unique 
codes that do not contain information that could identify you.  A link to this code does exist.  The 
link is stored at the Data and Coordinating Center for the Blood and Marrow Transplant Clinical 
Trials Network (BMT CTN).  The staff at the repository where your sample is being stored does 
not have a link to this code.  Your samples will be stored at this repository until the samples have 
been used for the research tests or until the end of the study.  Any research performed on the 
samples must first be approved by [CONTACT_501817].  
 The research that may be done with your blood is not designed specifically to help you.  It might 
help people who have GVHD, cancer and other diseases in the future.  
 
Reports about research done with your blood will not be given to you or your doctor.  These 
reports will not be put in your health record.  The research will not have an effect on your care.  
 
Things to Think About: The choice to let us have blood samples for future research is up to 
you.  No matter what you decide to do, it will not affect your care.  
 
If you decide now that your blood can be kept for research, you can change your mind at any 
time.  Just contact [CONTACT_501818].  Then any blood that remains will no longer be used for research.  
 
In the future, people who do research on these blood samples may need to know more about your 
health.  While the study doctor or others involved in running this study may give the researchers 
reports about your health, it will not give them your name, address, phone number, or any other 
information that will let the researchers know who you are.  
 
Sometimes blood is used for genetic research (about diseases that are passed on in families).  
Even if your blood is used for this kind of research, the results will not be put in your health 
records.  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 13 of 19 Participant initials ______  
Your 
blood will be used only for research and will not be sold.  The research done with your 
blood may help to develop new products in the future.  
 
Benefits: The benefits of research using blood include learning more about what causes cancer 
and other diseases, how to prevent them, and how to treat them.  
 
Risks: The greatest risk to you is the release of information from your health records.  We will 
do our best to make sure that your personal information will be kept private.  The chance that 
this information will be given to someone else is very small.  
 
Making Your Choice: Please read each sentence below and think about your choice.  After 
reading each sentence, please indicate your choice below.  If you have any questions, please talk 
to your doctor or nurse, or call our research review board at ___________________.  
 
No matter what you decide to do, it will not affect your care. 
 
 Ye
s, I agree to have small blood samples drawn for future research. 
 
 No,
 I do not agree to have small blood samples drawn for future research. 
 
 ____________________________________   _____________________________  
Signature [CONTACT_1782] 
****
******************************************** 
 
If
 you have any questions about this study, you may contact [CONTACT_34355] 
[INVESTIGATOR_98369]. 
 
If you have questions about your rights as a research participant, you may contact (INSERT 
CONTACT [CONTACT_7533]) 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 14 of 19 Participant initials ______ CONSENT 
AND ASSENT INSTRUCTIONS 
 
 
CONSENT : Subjects [ADDRESS_646541] line below.  For subjects 
under 18, consent is provided by [CONTACT_126422]. 
 
ASSENT : Is required for subjects under the age of 18, using the Assent Section on the 
following page. 
 
I 
have been informed about this study’s purpose, procedures, possible benefits and risks.  I 
have been given the chance to ask questions.  My questions have all been answered 
satisfactorily.  I understand that I can ask other questions at any time. 
 
I voluntarily agree to take part, or to allow my child to take part, in this study. 
 
By [CONTACT_50841], I have not given up any of the legal rights that I (my child) 
otherwise would have as a subject in a research study. 
 
 
            
Subjec
t‘s Signature      [CONTACT_501830], please print your name      
[CONTACT_501831]: 
 
  T
he subject’s parent     
   The subject’s guardian 
  A
 surrogate      
   A durable power of attorney 
  A
 proxy      
   Other, please explain: 
  
       
     
Legally 
Authorized Representative Signature  [CONTACT_501832] a representative of this study, I have explained the purpose, the procedures, the benefits, 
and the risks that are involved in this research study: 
 
 
            
Si
gnature of person conducting informed consent  Date 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 15 of 19 Participant initials ______  
ASS
ENT SIGNATURES:   For subjects under the age of [ADDRESS_646542] been told that I don’t 
have to be in this study.  I may quit the study at any time, and no one will be mad at me.  I 
have had a chance to discuss the study and ask questions.  My questions have been answered.  I agree to be in the study and do what I am asked to do so long as I continue in the study. 
 
      
       
Si
gnature of Minor    Date   Age (years) 
Study Personnel 
 
 I have explained the purposes, procedures, and risks involved in this research study in detail 
to: 
 
               
       
Print na
me(s) of Parents/Authorized Consenting Party, and  
 
who in my opi[INVESTIGATOR_126372]/ IS 
NOT capable of assenting to participate in this study. 
 
 
Print child’s name 
 
 
            
[CONTACT_501833]
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page [ADDRESS_646543] Transplant Procedure 
 
 
There are certain risks related to a peripheral blood stem cell (PBSC) transplant.  There are risks 
from the medications and/or irradiation therapy you will receive as part of the conditioning for 
the transplant, and risks related to the transplant itself.  Most of these risks and side effects are 
listed below, but they will vary from person to person.  There may be more risks involved with 
transplantation, and there may be more side effects.  Your doctor may give you medications to 
lessen some of the side-effects.  
 
Risks Related to the Transplant Conditioning Regimen  
 
Yo
u and your doctor will choose a conditioning regimen that may include some of the 
follo
wing therapi[INVESTIGATOR_014].  
 
Cyclop
hosphamide (Cytoxan):  This is a common medication used to treat cancer.  This 
medication kills cancer cells by [CONTACT_13635][INVESTIGATOR_334205].  Cyclophosphamide may cause you to have diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting (throwing up), 
short-term hair loss, short-term bladder problems, and, at times, bleeding from the bladder.  A 
few patients may have bladder damage and bleeding for a longer time.  You will be given large 
amounts of a sterile solution through your central line to protect your bladder.  A bladder 
catheter (thin plastic tube) may be inserted into your bladder, if your physician thinks that it can 
help you.  Cyclophosphamide slows the making of new red blood cells, white blood cells, and platelets.  This causes a risk of infection and/or severe bleeding until the transplanted donor cells 
begin to work in you.  You will get blood transfusions as needed.  Cyclophosphamide also 
lowers your defense system.  As a result, you may have more infections for several months after 
transplant.  In a small number of patients, cyclophosphamide can damage the heart muscle 
causing heart failure.  Sometimes cyclophosphamide causes abnormal heart function.  If this 
occurs you may have shortness of breath and have fluids build-up in your body.  This medication 
can also cause the lungs to become scarred.  If scarring of the lungs occurs it will usually happen 
three to six months after you receive the medication.  Scarring of the lungs can cause death.  
Cyclophosphamide can damage the male (testes) or female (ovaries) sex glands.  In men, the 
number of sperm may be reduced but you would still be able to have intercourse.  Women who 
are still menstruating may have irregular periods or may no longer have any periods.  Whether 
you are a man or woman, this medication will likely greatly decrease your chances of being able 
to have a child.  It is not known whether the use of cyclophosphamide will cause more side 
effects or problems with your health in the future. 
 
Etoposide (VP-16):  This medication disrupts the growth of cancer cells and destroys them.  
While taking etoposide you most likely will have diarrhea (loose stools), nausea (feeling sick to 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 17 of 19 Participant initials ______ y
our stomach), vomiting (throwing up), lower white blood cell count that increases your risk of 
infection, lower platelet count that increases your risk of bleeding, hair loss, stoppi[INVESTIGATOR_501780], temporary reduced or no sperm production in men.  Less likely side 
effects that you may experience are fatigue, sores in the mouth or on the lips, fever, rash, and 
loss of appetite. Rare side effects that you may experience are damage to your heart, which may 
result in a heart attack or heart failure.  Your blood pressure may fall during the infusion of 
etoposide, and etoposide rarely causes numbness and tingling in the fingers and toes, in a 
condition termed, neuropathy.  This may be reversible.  Etoposide can rarely cause changes in 
your liver function. 
 
Total Body Irradiation (TBI):   TBI may cause you to have diarrhea (loose stools), nausea 
(feeling sick to your stomach), vomiting (throwing up), and painful swelling of the saliva gland 
for a few days.  You may also experience short-term hair loss.  TBI kills both sick and normal 
marrow, leading to a lack of red blood cells, white blood cells, and platelets.  The short-term loss 
of these blood cells could cause you to become anemic, develop an infection, and/or bleeding.  
This will continue until the transplanted donor cells begin to work in you.  You will get blood 
transfusions as needed.  There is a risk that cataracts (cloudiness) may develop in your eyes.  
This may mean partial loss of vision, and you may need contact [CONTACT_501819].  The TBI dose used will probably result in sterility (not being able to have children.)  It 
is not known whether the use of TBI will cause more side effects or problems with your health in 
the future. 
 
The conditioning regimens allowed by [CONTACT_501820]-
mature menopause.  Men who receive these conditioning regimens are unlikely to be able to 
father children.  However, there is no guarantee that this will happen to you, so you should 
discuss the need for birth control with your doctor.  In any case, you are not protected from sexually transmitted diseases as a result of having these treatments. 
 
Risks Related to the Infusion Peripheral Blood Stem Cells (PBSC)
 
 T
he infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may 
cause a headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause an allergic reaction (which shows up as a severe drop in blood pressure and 
may cause loss of consciousness).   
 
Risks Related to the Transplant Procedure
 
 
T
he following risks are not specifically related to any one medication or the transplanted donor 
cells, but they are risks that are a part of the transplant procedure. 
 
Bleeding:  Platelets help your blood to clot.  Your platelets will be low until the new bone 
marrow grows and, as a result, bleeding may occur.  This can be minor bleeding, such as 
nosebleeds or bruising, but more serious, life-threatening bleeding in the lungs and brain can 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 18 of 19 Participant initials ______ o
ccur if the platelet count remains low.  Usually, there is success in preventing major bleeding 
problems with transfusions of platelets.  However, some patients may not respond well to 
transfused platelets and may be at serious risk for bleeding.  
 
Veno-Occlusive Disease (VOD):  This can occur as a result of high dose chemotherapy, 
irradiation therapy, or both.  VOD causes severe damage to the liver.  Symptoms include 
jaundice (yellowing of the skin and eyes), weight gain, and extra fluid build-up in the abdominal 
cavity and other parts of the body.  It can often be managed successfully, and completely resolve.  
However, complications can arise that may be fatal. 
 
Mouth Sores and Diarrhea:  The large doses of medicines and irradiation cause irritation in the 
lining of the mouth and intestines.  This can result in painful mouth sores and diarrhea.  If you 
have severe mouth sores you will be given medicine to help control the pain.  If your mouth 
sores are severe you may not be able to eat normally until the sores are healed.  Mouth sores get 
better when the white blood count starts to rise, and engraftment occurs. 
 
Capi[INVESTIGATOR_92306]:  This may occur as a result of chemotherapy and irradiation therapy.  
The blood vessels may become ‘leaky’ and fluid enters the abdominal cavity, lungs, and other 
tissues.  You may gain water weight and not go to the bathroom as often as you normally do.  
Capi[INVESTIGATOR_126373].  You may die if there is continued fluid collection in the lungs.  
 
Unexpected Organ Damage and Other Side Effects:  It is possible you may experience 
unexpected, life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  
Occasionally, the high doses of chemotherapy and radiation cause severe lung damage that 
cannot always be treated.  If this happens, you may need to use oxygen or even a respi[INVESTIGATOR_13521].  The lung damage may get worse and be life-threatening.  Rarely, multi-organ failure (such as lung 
and kidney failure) may occur, which is often fatal.  A form of kidney failure, called thrombotic 
microangiopathy may result in reversible or irreversible kidney damage, and may require 
temporary or permanent dialysis therapy. 
 
Late Effects:  You may experience side effects that occur several months to many years after 
your transplant.  You may experience poor function of the thyroid gland, requiring you to take 
thyroid medication.  Poor thyroid function can result in fatigue, weight gain, hair loss, 
depression, dry skin and dry hair; however, this is easily corrected by [CONTACT_59600].  As a result 
of irradiation, cataracts may occur earlier in life compared to a person who had not had a 
transplant.  If you develop cataracts (cloudiness in the eyes) they may require treatment.  It is 
rare, but your kidneys could be affected, causing anemia (low red blood cell count) or high blood 
pressure.  There is also a risk you may develop a second cancer as a result of the chemotherapy, 
irradiation and/or underlying disease.  If secondary cancers occur they generally do not occur 
until 10 to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are 
unknown. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Partic
ipant Consent Page 19 of 19 Participant initials ______ Flu
id Build-up:  You will receive intravenous fluids during the transplant process and you may 
have difficulty eliminating this fluid.  Furosemide is a medication that is often given to help 
eliminate this excess fluid.  This medication may cause hearing loss and loss of body chemicals 
such as potassium and sodium. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Donor
 Consent Page 1 of 6 Donor initials ______ In
formed Consent to Participate in Research  
 
Study
 Title : A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus with 
Tacrolimus/Methotrexate as GVHD Prophylaxis After HLA-Matched, Related Peripheral Blood 
Stem Cell Transplantation  
 
Principal Investigator [INVESTIGATOR_41863]: ( Insert contact [CONTACT_29073] [INVESTIGATOR_29061].) 
 
Introduction 
We invite you to take part in a research study sponsored by [CONTACT_7681] 
(NIH) and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). 
 
First, we want you to know that: 
 Taking part in NIH research is entirely voluntary. 
 You may choose not to take part, or you may withdraw from the study at any time.  In either case, you will not lose any benefits to which you are otherwise entitled.  
 You may receive no benefit from taking part.  The research may give us knowledge 
that may help people in the future. 
 
Second, some people have personal, religious or ethical beliefs that may limit the kinds of 
medical or research treatments they would want to receive (such as blood transfusions).  If you 
have such beliefs, please discuss them with your doctors or research team before you agree to the 
study. 
 
Now we will describe this research study.  Before you decide to take part, please take as much 
time as you need to ask any questions and discuss this study with your family, friends, or your 
personal physician or other health professional. 
 
 
Purpose 
During the course of this study, we will attempt to learn about genetic factors that may have an 
influence on the risks of Graft-vs-Host Disease (GVHD) and long-term outcome after allogeneic 
stem cell transplantation.  GVHD is an immune reaction that occurs after transplantation of stem 
cells from one individual (the donor) to another (the recipi[INVESTIGATOR_841]).  GVHD is a form of rejection of 
the recipi[INVESTIGATOR_110833] (such as the skin, the intestinal tract and the liver) by [CONTACT_501821].  We are interested in studying the small variations or differences in genes, called 
polymorphisms or variants that could influence the immune system to cause GVHD.  At this 
time, there are several candidate genes that may influence the incidence of GVHD.  We would 
like to store your DNA (which will be isolated from your blood) to eventually study some of 
these genes.  We invite you to participate in this study so that we can learn more about these 
genetic factors. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Donor
 Consent Page 2 of 6 Donor initials ______  
 
Pro
cedures 
Sixteen (16) milliliters of blood will be used for the genetic analysis.  We ask that you submit a 
sample of no more than 16 mL, equivalent to three teaspoons.  For donors less than 12 years old, 
a sample of no more than 8 mL, equivalent to 1½ teaspoons, will be requested.  If you withdraw 
from the study, your samples will not be used for other research studies or tested further.   
 
Clinical information (e.g., HLA typi[INVESTIGATOR_007]) about you will be collected.  The NIH will not have 
access to the names of the patients enrolled in this study.  The clinical information will be coded 
and compared to the genetic analysis at a later date.   
 
The samples collected for research purposes will be sent to laboratories that have contracts with 
the BMT CTN to conduct these research tests.  They will be labeled with unique codes that do 
not contain information that could identify you.  The link is stored at the Data Coordinating 
Center for the BMT CTN.  The staff at the laboratories where your samples are being tested do 
not have a link to this code.   
 
In the laboratory, we will isolate DNA from your blood.  At a later date, we will test the DNA 
for the polymorphisms in your genes and in the genes in your stem cell recipi[INVESTIGATOR_841].  The 
polymorphisms will be correlated with clinical outcomes after transplantation. 
 
Your samples will be stored at these laboratories until the entire sample has been used for the 
research tests or until the end of the study.  If any of your samples are leftover after the research 
studies are completed, these samples will either be destroyed or be sent to the National Heart 
Lung and Blood Institute (NHLBI) sample repository in Maryland.  If your leftover samples are sent to the repository, they will be given an anonymous code.  These leftover samples stored at 
the repository can never be linked to you.  Any research performed on these leftover samples 
must first be approved by [CONTACT_501817]. 
 
If you agree to allow your blood to be kept for research, you are free to change your mind at any 
time.  We ask that you tell [the Principal Investigator] at [address] in writing and let him/her 
know you are withdrawing your permission for your sample to be used for research.  Any unused 
sample will be destroyed. 
 
 
Alternatives 
You may choose not to participate in this part of the study.  The decision to participate in this 
study will not affect the care given to you by [CONTACT_501822].  
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Donor
 Consent Page [ADDRESS_646544] recent information.   
 
 HIPAA
2 A
UTHORIZATION TO USE AND DISCLOSE INDIVIDUAL HEALTH 
INFORMATION FOR RESEARCH PURPOSES 
 
1. Purpose:  As a research participant, I authorize the Principal Investigator [INVESTIGATOR_29062]’s 
staff to use and disclose my individual health information for the purpose of conducting the 
research study entitled A Phase III Randomized, Multicenter Trial Comparing 
Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as GVHD Prophylaxis After HLA-
Matched, Related Peripheral Blood Stem Cell Transplantation.  
 
2. Individual Health Information to be Used or Disclosed:  My individual health information that 
may be used or disclosed to conduct this research includes: Demographic information (e.g., 
age, date of birth, sex, weight), medical history, physical examination findings, and genetic 
test results.  
 
 
                                                   
[ADDRESS_646545] of 1996, a federal law related to privacy of health 
information.  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Donor
 Consent Page 4 of 6 Donor initials ______ 3. Partie
s Who May Disclose My Individual Health Information:  The researcher and the 
researcher’s staff may obtain my individual health information from ( list hospi[INVESTIGATOR_600], clinics or 
providers from which health care information can be requested):  
 
___________________________________________________________________ 
 
___________________________________________________________________ 
 
___________________________________________________________________ 
 
 
4. Parties Who May Receive or Use My Individual Health Information:  The individual health 
information disclosed by [CONTACT_29085] 3 and information disclosed by [CONTACT_98410]: 
 Principal Investigators and the researcher’s staff, including [CONTACT_501834] and [CONTACT_501836], Study Chairpersons and staff/laboratories at Dana Farber Cancer 
Institute 
 National Heart, Lung and Blood Institute (NHLBI) and National Cancer Institute 
(NCI), both of the National Institutes of Health (NIH), study sponsors  
 Blood and Marrow Transplant Clinical Trials Network (BMT CTN), data 
coordinating center 
 U.S. government agencies that are responsible for overseeing research such as the 
Food and Drug Administration (FDA) and the Office of Human Research Protections 
(OHRP) 
 U.S. government agencies responsible for overseeing public health concerns such as 
the Centers for Disease Control (CDC) and federal, state and local health 
departments. 
 
5. Right to Refuse to Sign this Authorization:  I do not have to sign this Authorization.  If I 
decide not to sign the Authorization, I will not be allowed to participate in this study or receive any research-related treatment that is provided through the study.  However, my 
decision not to sign this authorization will not affect any other treatment, payment, or 
enrollment in health plans or eligibility for benefits.   
 
6. Right to Revoke:   I can change my mind and withdraw this authorization at any time by 
[CONTACT_5583] a written notice to the Principal Investigator [INVESTIGATOR_98364].  
If I withdraw this authorization, the researcher may only use and disclose the protected health 
information already collected for this research study.  No further health information about me 
will be collected by [CONTACT_98411]. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Donor
 Consent Page 5 of 6 Donor initials ______ 7. Po
tential for Re-disclosure: My individual health information disclosed under this 
authorization may be subject to re-disclosure outside the research study and no longer 
protected.  Examples include potential disclosures for law enforcement purposes, mandated 
reporting or abuse or neglect, judicial proceedings, health oversight activities and public 
health measures. 
 
8. DNA from your stored blood sample might be used in genome-wide association (GWA) or 
pharmacogenomics studies for a future project either done or supported by [CONTACT_66121] (NIH).  Genome-wide association studies are a way for scientists to 
identify genes involved in human disease.  This method searches the genome for small 
genetic changes that are more common in people with a particular disease than in people 
without the disease.  Each study can look at hundreds of thousands of genetic changes at the 
same time.  Researchers use data from this type of study to find genes that may add to a 
person’s risk of developi[INVESTIGATOR_007] a certain disease.  Pharmacogenomics studies are similar genetic 
tests but look specifically at genes related to how the body breaks down medications.  
 
If your coded samples are used in such a study, the researcher is required to add your test 
results and sample information into a shared, public research database.  This public database 
is called the NIH Genotype and Phenotype Database and it is managed by [CONTACT_501823] (NCBI).  The NCBI will never have any information 
that would identify you, or link you to your information or research samples.  
 
9. A new federal law (2009), called the Genetic Information Nondiscrimination Act (GINA) 
generally makes it illegal for health insurance companies, group health plans, and employers 
of [ADDRESS_646546] an expi[INVESTIGATOR_320]. 
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
  IRB
 # 
 
 
Donor
 Consent Page [ADDRESS_646547] (either 
favorably or unfavorably) the willingness of the insurance company to sell you insurance. 
 The Federal Privacy Act protects the confidentiality of your NIH medical records.  However, you should know that the Act 
allows release of some information from your medical record without your permission, for example, if it is required by [CONTACT_86959] (FDA), members of Congress, law enforcement officials, or other authorized people. 
 
2. 
 Policy Regarding Research-Related Injuries.   The Clinical Center will provide short-term medical care for any injury 
resulting from your participation in research here.  In general, no long-term medical care or financial compensation for research-related injuries will be provided by [CONTACT_7681], the Clinical Center, or the Federal Government.  However, 
you have the right to pursue legal remedy if you believe that your injury justifies such action. 
 
3.  P
ayments.   The amount of payment to research volunteers is guided by [CONTACT_33878].  In general, 
patients are not paid for taking part in research studies at the National Institutes of Health. 
 
4. 
 Problems or Questions.   If you have any problems or questions about this study, or about your rights as a research 
participant, or about any research-related injury, contact [CONTACT_77714][INVESTIGATOR_136]or [INVESTIGATOR_136] (xxx) xxx-xxxx. 
 
5.  Consent D
ocument.   Please keep a copy of this document in case you want to read it again. 
 
CO
MPLETE APPROPRIATE ITEM BELOW, A or B  
A
. Adult Patient's Consent.  
I
 have read the explanation about this study and have been 
given the opportunity to discuss it and to ask questions. I 
hereby [CONTACT_107771].  
 
Si
gnature of Adult Patient & Date Signed 
 
 
 
T
HIS CONSENT DOCUMENT HAS BEEN APPROVED 
FOR USE FROM _________ THROUGH __________. B. Parent's Permission for Minor Patient.  
I
 have read the explanation about this study and have been 
given the opportunity to discuss it and to ask questions. I 
hereby [CONTACT_477350]. (Attach NIH 2514-2, Minor’s Assent, if applicable) 
 
Si
gnature of Parent(s)/Guardian & Date Signed 
If other than parent, specify relationship:   
 
 Child's V
erbal Assent (if applicable).  
T
he information in the above consent form has been 
adequately described to my child in language that my child 
can understand, and my child willingly agrees to participate in the study. 
 
Si
gnature of Parent(s)/Guardian & Date Signed  
 
Si
gnature of Investigator & Date Signed   
Si
gnature of Witness & Date Signed  
 
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
C-1  
   
APPENDI
X C 
 
LABORATORY SAMPLES  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
C-2 APPEND
IX C 
 
LABORATORY SAMPLES  
  
1. HLA TYPIN
G 
 
Before Transplantation:  HLA typi[INVESTIGATOR_126375] (ASHI)-approved laboratories 
designated by [CONTACT_126423].  HLA typi[INVESTIGATOR_501781] (or higher 
resolution) methods for HLA-A and B, and molecular typi[INVESTIGATOR_501782]1 consistent with NMDP 
standard procedures. 
 
 
2. PATHOLOGY/CYTOGENETICS STUDIES 
 
A bone marrow biopsy/aspi[INVESTIGATOR_501783].  A bone marrow aspi[INVESTIGATOR_501784] [ADDRESS_646548] transplant. 
 
Pathology and cytogenetic studies will be conducted per institutional guidelines. 
  
3. FLOW CYTOMETRY/IMMUNE RECONSTITUTION ASSAY 
 Flow cytometry on peripheral blood specimens from the patient will be performed at the 
following timepoints: Day 28, Day 100, Day 180, Day 365 and Day 730. 
Tubes will be collected and shipped to: 
 
Esoterix Clinical Trials Services 
Attn: Shiela Rines 
[ADDRESS_646549], NJ  [ZIP_CODE] 
 
Assays will be performed to determine the number of CD2, CD3, CD4, CD8, CD19, CD25, 
CD45Ro/Ra and CD56 cells. 
 
Immunophenotype assays of lymphoid subsets and dendritic cells:  Samples of peripheral 
blood will be obtained from patients at 28, 100, 180, [ADDRESS_646550]-transplant.  Sample 
processing and testing should be performed as quickly after sample receipt as possible.  
Laboratory will perform and report to EMMES a complete blood count (CBC) and manual
 cel
l 
differential & morphology assessment on the EDTA containing samples submitted at each time 
point. Laboratory will calculate the absolute numbers of subsets of immune cells in the blood 
based upon the absolute number of leukocytes in the blood and the percentage of leukocytes that 
are T, B, NK, monocyte, or dendritic cell subsets as defined by [CONTACT_83549].  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
C-3 T
he flow cytometric analysis will be performed using a panel of flow cytometry assays, each 
containing multiple fluorescently labeled monoclonal antibodies.  The FACS panel that will be 
used is shown below.  Please note that all necessary controls are not shown in this table. 
 
 
Flow Cytometry for Immune Reconstitution 
 
T
ube  
# Class of  
Ce
lls Cell Types M
easured Bl oo
d Cell 
Subset
s Antibodies 
1 Lym
phoid 
Subsets T
 cells  CD4 
CD8 
CD25+  an
ti-CD4(Per
CP) 
an
ti-CD8 (FITC) 
anti-CD25 (PE) 
anti-CD3(APC) 
2 Lym
phoid 
Subsets NK
 and  T cells CD56+  
 T
 cells an
ti-CD56 (PE)  
an
ti- TCR (FITC) 
anti-CD16 (PerCP) anti-CD3 (APC) 
3 Lym
phoid 
Subsets CD8 T
 cell 
Subsets Na
ïve and activated CD8 
T
 cells an
ti-CD8 (A
PC) 
an
ti-Ki67(FITC) 
anti-CD62L (PE) anti-CD45RA (TC) 
4 Lym
phoid 
Subsets CD4 T  ce
ll 
Subsets Na
ïve and activated CD4 
T
 cells an
ti-CD4 (A
PC) 
an
ti-Ki67(FITC) 
anti-CD62L(PE) anti-CD45RA (TC) 
5 Lym
phoid 
Subsets B-ce
lls & 
m
onocytes CD5+  
CD27 B ce
lls 
CD14+ monocytes an
ti-CD5 (Per
CP) 
an
ti-CD27 (FITC) 
anti-CD14(PE) anti-CD19 (APC) 
6 De
ndritic Cell 
Subsets DC subsets  DC1 a
nd DC2 subsets  an
ti-linea
ge (FITC)  
an
ti-CD123(PE) 
anti-HLADR (PerCP) anti-CD11c(APC) 
7 I
sotype 
Controls I
sotype Ig  Non-spec
ific staining  irr
elevant (FITC) (PE) (PerCP)  
(A
PC) conjugates to murine 
monoclonal Ab 
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646551] categories.  Polymorphisms in cytokine genes 
(such as IL-6, IL-10 and others) have been linked to differences in acute
1-[ADDRESS_646552] 
polymorphisms are in the family of the Natural Killer (NK) cell receptor and ligand group, 
collectively termed the Killer Immunoglobulin-like Receptor (KIR) family, which have been 
linked to differences to both GVHD and relapse rates after transplantation.[ADDRESS_646553] donor samples for DNA and serum banking, from which 
studies of these polymorphisms can be performed.  Since the results of the polymorphism 
analysis will be correlated with clinical results after transplantation, the samples will be stored at 
the time of stem cell donation, and will be analyzed at a later date, when transplant outcomes can 
be measured. 
 
Research Plan  
 
Prior to administration of G-CSF, donors will provide 16 mL (or 8 mL for donors less than 12 
years old) of peripheral blood.  The center may make further adjustments in blood volumes 
collected from patients less than 12 years old to meet the institution’s Human Investigational 
Committee’s Guidelines.  The samples will be processed, stored under appropriate conditions, 
and shipped quarterly to the NHLBI repository.  No analysis will occur until all samples have 
been received and pertinent research questions have been developed.   
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646554] with the NMDP on behalf of the BMT CTN. 
 
Frozen samples should be batched and shipped quarterly to the Repository in compliance with 
the shippi[INVESTIGATOR_501785] 0402 Laboratory 
Sample Information Guide:  
 
Christina Demasco NHLBI Repository 
SeraCare BioServices 
[ADDRESS_646555] 
Gaithersburg, Maryland  [ZIP_CODE] 
Phone: ([PHONE_10409] 
Fax: ([PHONE_10410] 
Email: [EMAIL_9552] 
BMT CLINICA
L TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646556]  
Locat
ion 
H
LA Typi[INVESTIGATOR_501786]. N/A Transplant 
Center 
Pat
hology/ 
Cytogenetic Studies According to 
institutional practice According to institutional 
practice Within four weeks prior to 
the initiation of 
conditioning therapy and on 
Day 100, [ADDRESS_646557]-
transplant. N/A Transplant 
Center 
Flo
w Cytometry/ 
Immune 
Reconstitution 8.5 mL peripheral 
blood  
8.5 mL Yellow Top 
ACD-A 
Anticoagulation 
Vacutainer  
(003 IR-Blood V) No additional processing –  
do not centifuge. Day 28, 100, 180, [ADDRESS_646558]-transplant. Shipped 
overnight on cold 
ice packs (4°C) Esoterix 
Clinical 
Trials 
Services 
3
 mL peripheral 
blood  
3 mL Lavendar Top 
EDTA 
Anticoagulation 
Vacutainer  
(004 IR-Blood V) No additional processing –  
do not centifuge. Day 28, 100, 180, [ADDRESS_646559]-transplant. Shipped 
overnight on cold 
ice packs (4°C) Esoterix 
Clinical 
Trials 
Services 
BMT CLINICA
L TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646560]  
Locat
ion 
In
vestigational 
Future Testing 10 mL peripheral 
blood (10 mL red 
top tube) 
OR 
5 mL peripheral 
blood (6 mL red top 
tube) for patients  
< [ADDRESS_646561] serum, transfer 500 ul 
aliquots to 10 cryovials2. 
Stor
e at -70° C. Baseline (prior to the 
initiation of conditioning 
therapy) and on Day 28, 
100, 180, [ADDRESS_646562]-
transplant. Frozen shipment 
quarterly to 
Repository in 
compliance with 
shippi[INVESTIGATOR_501787] 
6
 mL peripheral 
blood (7 mL 
lavender top tube)  
OR 
3 mL peripheral 
blood (4 mL 
lavender top tube) 
for patients  
< [ADDRESS_646563] 
plasma, transfer 500 ul aliquots 
to 6 cryovials2. 
Stor
e at -70° C. Baseline (prior to the 
initiation of conditioning 
therapy) and on Day 28, 
100, 180, [ADDRESS_646564]-
transplant. Frozen shipment 
quarterly to 
Repository in 
compliance with 
shippi[INVESTIGATOR_501788]
L TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646565]  
Locat
ion 
Do
nor Genetic 
Studies 10 mL peripheral 
blood (10 mL 
lavendar top tube) 
OR 
5 mL peripheral 
blood (6 mL 
lavendar top tube) 
for donors  
< [ADDRESS_646566] pasma, transfer 500 ul 
aliquots to 10 cryovials. 
Store at -70° C. 
Resuspend cellular component 
in RBC lysis buffer, divide and 
transfer into [ADDRESS_646567] buffer and 
freeze pellet at -70° C 
immediately. Prior to administration of 
G-CSF Frozen shipment 
quarterly to 
Repository in 
compliance with 
shippi[INVESTIGATOR_501789]: 
1 The 
center may make further adjustments in blood volumes collected from patients less than 12 years old to meet the institution’s Human 
Investigational Committee’s Guidelines. 
2 Us
e half of the amount of cryovials for patients less than 12 years old. 
  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646568]  
 
 (1)  Cavet J, Middleton PG, Segall M et al. Recipi[INVESTIGATOR_501790]-alpha and 
interleukin-[ADDRESS_646569] disease severity in HLA-matched sibling bone marrow transplants. Blood. 
1999;94:3941-3946. 
 (2)  Cavet J, Dickinson AM, Norden J et al. Interferon-gamma and interleukin-[ADDRESS_646570] disease in HLA-matched sibling bone 
marrow transplantation. Blood. 2001;98:1594-1600. 
 (3)  Cullup H, Dickinson AM, Jackson GH et al. Donor interleukin [ADDRESS_646571] disease in human leucocyte antigen-
matched sibling allogeneic transplants. Br J Haematol. 2001;113:807-813. 
 (4)  Hattori H, Matsuzaki A, Suminoe A et al. Polymorphisms of transforming growth factor-
beta1 and transforming growth factor-beta1 type II receptor genes are associated with acute graft-versus-host disease in children with HLA-matched sibling bone marrow 
transplantation. Bone Marrow Transplant. 2002;30:665-671. 
 (5)  Karabon L, Wysoczanska B, Bogunia-Kubik K, Suchnicki K, Lange A. IL-[ADDRESS_646572] disease. Hum 
Immunol. 2005;66:700-710. 
 (6)  Lin MT, Storer B, Martin PJ et al. Relation of an interleukin-[ADDRESS_646573] disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003;349:2201-2210. 
 (7)  Lin MT, Storer B, Martin PJ et al. Genetic variation in the IL-[ADDRESS_646574] disease following hematopoietic cell transplantation: 
synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. 
Blood. 2005;106:3995-4001. 
 (8)  MacMillan ML, Radloff GA, Kiffmeyer WR et al. High-producer interleukin-[ADDRESS_646575] disease after unrelated donor bone marrow transplantation. Transplantation. 2003;76:1758-1762. 
 (9)  Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene 
polymorphisms associating with severe acute graft-versus-host disease in HLA-identical 
sibling transplants. Blood. 1998;92:3943-3948. 
 (10)  Mlynarczewska A, Wysoczanska B, Karabon L, Bogunia-Kubik K, Lange A. Lack of 
IFN-gamma 2/2 homozygous genotype independently of recipi[INVESTIGATOR_501791]-matched 
sibling haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;34:339-
344. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
C-1
1  (11
)  Nordlander A, Uzunel M, Mattsson J, Remberger M. The TNFd4 allele is correlated to 
moderate-to-severe acute graft-versus-host disease after allogeneic stem cell 
transplantation. Br J Haematol. 2002;119:1133-1136. 
 (12)  Stark GL, Dickinson AM, Jackson GH et al. Tumour necrosis factor receptor type II 
196M/R genotype correlates with circulating soluble receptor levels in normal subjects 
and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. 
Transplantation. 2003;76:1742-1749. 
 (13)  Takahashi H, Furukawa T, Hashimoto S et al. Contribution of TNF-alpha and IL-[ADDRESS_646576] disease following allo-hematopoietic stem cell 
transplantation. Bone Marrow Transplant. 2000;26:1317-1323. 
 (14)  Bogunia-Kubik K, Mlynarczewska A, Wysoczanska B, Lange A. Recipi[INVESTIGATOR_452792]-
gamma 3/[ADDRESS_646577] disease 
after allogeneic hematopoietic stem cell transplantation. Haematologica. 2005;90:425-
426. 
 (15)  Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG. Polymorphisms of 
interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol. 2003;122:778-787. 
 (16)  Kim DH, Lee NY, Sohn SK et al. IL-10 promoter gene polymorphism associated with the 
occurrence of chronic GVHD and its clinical course during systemic immunosuppressive 
treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. 
Transplantation. 2005;79:1615-1622. 
 (17)  Bogunia-Kubik K, Mlynarczewska A, Jaskula E, Lange A. The presence of IFNG 3/3 
genotype in the recipi[INVESTIGATOR_501792]-Barr virus reactivation 
after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2006;132:326-
332. 
 (18)  Seo KW, Kim DH, Sohn SK et al. Protective role of interleukin-10 promoter gene 
polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic 
stem cell transplantation. Bone Marrow Transplant. 2005;36:1089-1095. 
 (19)  Akatsuka Y, Warren EH, Gooley TA et al. Disparity for a newly identified minor 
histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after 
haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol. 
2003;123:671-675. 
 (20)  Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol. 1996;8:75-81. 
 (21)  Kernan NA, Dupont B. Minor histocompatibility antigens and marrow transplantation. N 
Engl J Med. 1996;334:323-324. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
C-1
2  (22
)  Kotzampasaki EM, Spyropoulou-Vlachou MS, Kalofoutis C et al. Minor 
histocompatibility antigen HA-1 and HPA-5 polymorphisms in HLA-identical related 
bone marrow transplantation. Transplant Proc. 2004;36:1735-1738. 
 (23)  Miklos DB, Kim HT, Miller KH et al. Antibody responses to H-Y minor 
histocompatibility antigens correlate with chronic graft-versus-host disease and disease 
remission. Blood. 2005;105:2973-2978. 
 (24)  Chen C, Huang SL. Killer cell inhibitory receptors involved in graft-versus-host disease 
and graft-versus-leukemia effect in allogeneic hematopoietic stem cell transplantation - 
review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004;12:236-243. 
 (25)  Gagne K, Brizard G, Gueglio B et al. Relevance of KIR gene polymorphisms in bone 
marrow transplantation outcome. Hum Immunol. 2002;63:271-280. 
 (26)  Beelen DW, Ottinger HD, Ferencik S et al. Genotypic inhibitory killer immunoglobulin-
like receptor ligand incompatibility enhances the long-term antileukemic effect of 
unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid 
leukemias. Blood. 2005;105:2594-2600. 
 (27)  Igarashi T, Wynberg J, Srinivasan R et al. Enhanced cytotoxicity of allogeneic NK cells 
with killer immunoglobulin-like receptor ligand incompatibility against melanoma and 
renal cell carcinoma cells. Blood. 2004;104:170-177. 
 (28)  Schaffer M, Malmberg KJ, Ringden O, Ljunggren HG, Remberger M. Increased 
infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic 
stem-cell transplantation. Transplantation. 2004;78:1081-1085. 
 (29)  Bogunia-Kubik K, Lange A. HSP70-hom gene polymorphism in allogeneic 
hematopoietic stem-cell transplant recipi[INVESTIGATOR_501793]-versus-host disease. Transplantation. 2005;79:815-820. 
 (30)  Holler E, Rogler G, Herfarth H et al. Both donor and recipi[INVESTIGATOR_501794]2/CARD15 
mutations associate with transplant-related mortality and GvHD following allogeneic 
stem cell transplantation. Blood. 2004;104:889-894. 
 (31)  Middleton PG, Cullup H, Dickinson AM et al. Vitamin D receptor gene polymorphism 
associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic 
bone marrow transplantation. Bone Marrow Transplant. 2002;30:223-228. 
 (32)  Middleton PG, Norden J, Cullup H et al. Oestrogen receptor alpha gene polymorphism 
associates with occurrence of graft-versus-host disease and reduced survival in HLA-
matched sib-allo BMT. Bone Marrow Transplant. 2003;32:41-47. 
 (33)  Rozman P, Karas M, Kosir A et al. Are human platelet alloantigens (HPA) minor 
transplantation antigens in clinical bone marrow transplantation? Bone Marrow 
Transplant. 2003;31:497-506. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
C-1
3  (34
)  Kalayoglu-Besisik S, Caliskan Y, Sargin D, Gurses N, Ozbek U. 
Methylenetetrahydrofolate reductase C677T polymorphism and toxicity in allogeneic 
hematopoietic cell transplantation. Transplantation. 2003;76:1775-1777. 
 (35)  Robien K, Schubert MM, Bruemmer B et al. Predictors of oral mucositis in patients 
receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol. 
2004;22:1268-1275. 
 (36)  Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E. Genetic polymorphisms 
predicting the outcome of bone marrow transplants. Br J Haematol. 2004;127:479-490. 
 (37)  Kallianpur AR. Genomic screening and complications of hematopoietic stem cell 
transplantation: has the time come? Bone Marrow Transplant. 2005;35:1-16. 
 (38)  Socie G, Loiseau P, Tamouza R et al. Both genetic and clinical factors predict the 
development of graft-versus-host disease after allogeneic hematopoietic stem cell 
transplantation. Transplantation. 2001;72:699-706. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
D-1  
   
APPENDI
X D 
 
RECOMMENDED LEUCOVORIN RESCUE SCHEMA 
 
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
D-2 APPEND
IX D 
 
RECOMMENDED LEUCOVORIN RESCUE SCHEMA  
  
12
 hours after d+1 methotrexate Leucovorin 15 mg/m2 i
v q6h x 3 doses 
 Maximum single dose 30 mg 
 
12 hours after d+3 methotrexate Leucovorin 10 mg/m2 i
v q6h x 6 doses 
 Maximum single dose 25 mg 
 
24 hours after d+6, 11 methotrexate Leucovorin 10 mg/m2 i
v q6h x 8 doses 
 Maximum single dose 25 mg 
  Methotrexate levels are not reliable during leucovorin therapy. 
 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
E-1  
   
APPENDI
X E 
 
CONSENSUS GVHD GRADING 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646578]
age S
kin Liver Gut 
0 No
 rash due to GVHD Bilirubin 
< 2 mg/dL < 500 mL (5 mL/kg for patients under 12 years) diarrhea per day 
1 Macu
lopapular rash < 25% of 
body surface a Biliru
bin 
2-3 mg/dLb 500
 to 999 mL diarrhea per day c 
(5.
1-10 mL/kg for patients under 12 
years), or persistent nausea with histologic evidence of GVHD in stomach or duodenum 
2 Macu
lopapular rash 25-50% of 
body surface a Biliru
bin 
3.1-6 mg/dLb 1,0
00 to 1,499 mL diarrhea per day 
(10.1-15.0 mL/ kg for patients under 12 years) 
3 Macu
lopapular rash > 50% of 
body surface a Biliru
bin 
6.1-15 mg/dL b 1,5
00 or more mL diarrhea per day c 
(m
ore than 15.0 mL/kg for patients under 
12 years of age) 
4 Gen
eralized erythroderma with 
bullous formation Bilirubin > 15 mg/dL
b Sev
ere abdominal pain with or without 
ileus 
a Us
e “Rule of Nines” to determine extent of rash. 
b Rang
e given as total bilirubin.  Downgrade one stage if an additional cause of elevated bilirubin has 
been documented. 
c Do
wngrade one stage if an additional cause of diarrhea has been documented. 
 
 
Ov
erall Clinical Grading of Severity of Acute GVHD 
 
Gr
ade  Degree of Organ Involvement 
0  No
 Stage 1-4 of any organ 
I  Stage 
1-2 rash and no liver or gut involvement  
II  Stage 
3 rash, or Stage 1 liver involvement, or Stage 1 gut involvement  
II
I  None to Stage 3 skin rash with Stage 2-3 liver involvement, or Stage 2-4 gut 
involvement  
I
V  Stage 4 skin rash, or Stage 4 liver involvement 
  Ad
apted from Thomas et al. , NEJM, 1975, pp. 895-90  
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
F-1  
   
APPENDI
X F 
 
MODIFIED OMAS 
 
MUCOSITIS SCORING SYSTEM 
 
SAMPLE CASE REPORT FORM 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
F-2 APPEND
IX F 
 
MODIFIED OMAS MUCOSITIS SCORING SYSTEM SAMPLE  
CASE REPORT FORM  
 
 
Si
te:     Protocol: 
Subject ID:    Date:   Assessor’s initials: 
 
 
Si
te Ulceration Erythema   
             
Max
illary labial mucosa Y     N Y     N NE*  
Mandi
bular labial 
mucosa Y     N Y     N NE 
Right
 cheek Y     N Y     N NE 
Left 
cheek Y     N Y     N NE 
Righ
t lateral  
& ventral tongue Y     N Y     N NE 
Left l
ateral  
& ventral tongue Y     N Y     N NE 
Fl
oor of mouth Y     N Y     N NE 
Soft 
palate Y     N Y     N NE 
          *
not evaluable 
 
 
Ability to eat:    solids   liquids     NPO        Mouth Pain       Y     N  
 
 
WHO 
score: 
0 Normal mucosa 
1 Erythema & mouth pain 
2 Ulceration & ability to eat solids 
3 Ulceration & liquids only 
4 Ulceration & NPO 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
G-1  
   
APPENDI
X G 
 
HUMAN SUBJECTS 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646579] 
consent : Candidates for the study will be identified as described in Chapter 4 of the 
protocol.  The Principal Investigator [INVESTIGATOR_022]/her designee at each transplant center will contact [CONTACT_501824].  The study coordinator at each center will provide the 
patient with information about the purpose of the study and obtain consent.  The Network will 
provide a template of the consent form to each center.  Each center will customize the template 
according to their local requirements and submit it for review by [CONTACT_110896] 
(IRB).  The DCC will verify the adequacy of the consent forms.  Each center must provide 
evidence of IRB approval.  
 
Confidentiality : Confidentiality will be maintained by [CONTACT_110897] a patient identifier code.  The code relaying the patient’s identity with the ID code will 
be kept separately at the center.  The ID code will be transmitted to the network.   
 
Participation of women, children, minorities and other populations : Women, children and 
ethnic minorities will be included in this study. 
 
Accrual will be monitored within each center with the expectation that the enrolled patient 
population is representative of the transplanted patient population at each center.  Representation 
will be examined by [CONTACT_110898], race, ethnicity and age distributions.  Accrual of 
minority patients will be expected to be in proportion to the number of minority patients 
transplanted at each center.  The DCC and NHLBI will discuss enrollment anomalies with the 
centers. 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
H-1  
   
APPENDI
X H 
 
GUIDELINES FOR SIMULTANEOUS USE OF SIROLIMUS AND 
ORAL VORICONAZOLE 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646580] initial treatment of invasive aspergillus1 a
nd other 
invasive fungal infections such as those caused by [CONTACT_501825]. and Scedosporium 
api[INVESTIGATOR_501795]2. 
 However, the use of voriconazole in combination with sirolimus was 
contraindicated at the time of voriconazole approval due to a substantial increase in sirolimus 
drug exposure in healthy subjects because voriconazole inhibits several CYP isoenzymes3. 
 This 
inhibition results in a sharp increase in sirolimus bioavailability; voriconazole increased 
sirolimus peak plasma concentration (C m
ax) 
and area under the plasma-concentration-time curve 
(AUC) by 6.6 fold and 11.1 fold, respectively 3
, 4. 
 Recently the group at Dana-Farber Cancer 
Institute has demonstrated that co-administration of voriconazole and sirolimus is safe if a 90% reduction in sirolimus dosing is undertaken
5. 
 Moreover, [COMPANY_007] Inc. has now undertaken a series 
of pharmacokinetic studies in normal volunteers that confirms that a 90% dose reduction of 
sirolimus results in reliable levels of sirolimus in the target range6. 
 The increase in 
bioavailability is due to transient inhibition of CYP enzymes in the intestinal mucosa.  Inhibition 
of liver CYP enzymes will prolong the half-life but not increase the bioavailability of the drug.  
The effects of intravenous voriconazole are less pronounced and dose modifications are not 
required when the intravenous formulation is used.  The effect of voriconazole on CYP is 
transient; therefore, if sirolimus and voriconazole are staggered there is a progressively less 
potent effect on sirolimus level.  If the drugs are staggered by [CONTACT_45848] [ADDRESS_646581] on bioavailability is less predictable.  
 
Suggested Dose Adjustments  
A
 90% dose reduction of sirolimus is an effective strategy for the co-administration of sirolimus 
and oral voriconazole.  Most adults receive sirolimus tablets, which have a minimum strength of 1 mg and which cannot be crushed or broken.  However, there is a liquid formulation of 
sirolimus at a concentration of 1 mg/mL.  An appropriate fractional dose can be drawn into a  
1 mL syringe and swallowed directly.  The liquid has an unpleasant taste that can be masked by 
[CONTACT_501826].  Alternatively, empty gelatin capsules can be dispensed along with the 
liquid sirolimus.  Because the drug is not in aqueous solution, the liquid can be placed in the 
capsule by [CONTACT_102], family member or health care provider without causing dissolution of the 
gelatin.  The capsule can then be taken orally.  Blood levels of sirolimus should be measured 
after the dosage change.  Changes in levels due to altered bioavailability should be apparent 
within 24-48 hours.  There will also be a prolongation of sirolimus half-life that may require 
dose adjustments in the weeks following the initiation of voriconazole therapy.  If voriconazole 
is stopped or changed to intravenous formulation, the dose of sirolimus should be increased by 
90% and blood levels should be monitored.  
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
H-3 Ex
ample : 
Patient is on 2 mg sirolimus daily. Voriconazole is taken at the same time as the 
sirolimus and the new sirolimus dose is 0.2 mg dispensed as 0.2 mL taken directly or placed in 
gelatin capsules. 
 
 
 
Endnotes for Appendix H 
 
1 He
rbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. 
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415. 
 
2 Center 
for Drug Evaluation and Research, FDA. NDA 21-266 and 21-267, VfendTM 
(Voriconazole). 24 May 2002  [Accessed [ADDRESS_646582] 2005]; Available from: http://www.fda.gov/cder/foi/appletter/2002/21266ltr.pdf; Perfect JR, Marr KA, Walsh TJ, 
Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less-
common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36(9):1122-1131. 
 
[ADDRESS_646583] Information: Vfend(R), voriconazole. [COMPANY_007] Inc, [LOCATION_001], NY, 2005. 
 
[ADDRESS_646584] of voriconazole on the pharmacokinetics of sirolimus 
(poster). In: 12th European Congress of Clinical Microbiology and Infectious Diseases; April 24-27, 2002; Milan, Italy; April 24-27, 2002.12. 
 
5 Marty
 FM, Lowry CM, Cutler CS, Campbell BJ, Fiumara K, Baden LR, Antin JH. 
Voriconazole and sirolimus co-administration following allogeneic hematopoietic stem cell 
transplantation. Biol Blood Marrow Transplant, 2006, in press. 
 
6 Bh
arat Damle, Clinical Pharmacology [COMPANY_007] Global Clinical Research and Development, 
personal communication. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
I-1  
   
APPENDI
X I 
 
REFERENCES 
 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
I-2 APPEND
IX I 
 
REFERENCES  
  
  
                                                 
1 Ch
amplin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow 
as a source of hematopoietic cells for allogeneic transplantation. Blood. 2000;95:3702-3709. 
2 Wei
sdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host 
disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75:1024-1030. 
[ADDRESS_646585] disease: secondary treatment. Blood. 1991;77:1821-1828. 
[ADDRESS_646586] disease. 
Expert Opin Pharmacother. 2001;2:1109-1117. 
[ADDRESS_646587] disease 
prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98:3192-
3204. 
[ADDRESS_646588] disease after marrow 
transplantation for leukemia. N Engl J Med. 1986;314:729-735. 
[ADDRESS_646589] J. Practical considerations in the use of 
tacrolimus for allogeneic marrow transplantation. Bone Marrow Transplant. 1999;24:1053-1056. 
[ADDRESS_646590] disease following allogeneic 
bone marrow transplantation in rats using FK506. Transplantation. 1991;52:590-594. 
[ADDRESS_646591] JR, Antin JH et al. FK506 (Tacrolimus) monotherapy for prevention of graft-
versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood. 1996;87:3514-3519. 
[ADDRESS_646592] disease after allogeneic bone marrow transplantation 
for leukemia. Bone Marrow Transplant. 1990;6:137-141. 
11 Storb
 R, Deeg HJ, Farewell V et al. Marrow transplantation for severe aplastic anemia: 
methotrexate alone compared with a combination of methotrexate and cyclosporine for 
prevention of acute graft-versus-host disease. Blood. 1986;68:119-125. 
[ADDRESS_646593] disease in 
bone marrow transplantation recipi[INVESTIGATOR_55508] a combination of cyclosporine and methotrexate. Transplant Proc. 1988;20:494-498. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol [ADDRESS_646594] disease after allogeneic 
peripheral- blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 
2001;19:3685-3691. 
14 Re
ynolds C, Ratanatharathorn V, Adams P et al. Comparative analysis of 
tacrolimus/methotrexate versus tacrolimus in allogeneic peripheral blood stem cell transplants:  Engraftment, GVHD, relapse, and survival outcomes. Blood. 1998;92:449a. 
[ADDRESS_646595] disease 
prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood 
Marrow Transplant. 2000;6:254-261. 
[ADDRESS_646596] disease: effect on 
chronic graft-vs.-host disease and long-term survival. Biol Blood Marrow Transplant. 
1999;5:285-291. 
17 Ratanath
arathorn V, Nash RA, Przepi[INVESTIGATOR_12776] D et al. Phase III study comparing methotrexate and 
tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease 
prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303-
2314. 
[ADDRESS_646597] disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062-2068. 
19 Hor
owitz MM, Przepi[INVESTIGATOR_12776] D, Bartels P et al. Tacrolimus vs. cyclosporine immunosuppression: 
results in advanced- stage disease compared with historical controls treated exclusively with 
cyclosporine. Biol Blood Marrow Transplant. 1999;5:180-186. 
20 Hiraoka 
A, Ohashi Y, Okamoto S et al. Phase III study comparing tacrolimus (FK506) with 
cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow 
transplantation. Bone Marrow Transplant. 2001;28:181-185. 
21 Davies
 SM, Kollman C, Anasetti C et al. Engraftment and survival after unrelated-donor bone 
marrow transplantation: a report from the national marrow donor program. Blood. 2000;96:4096-4102. 
22 Ho
 VT, Weller E, Lee SJ et al. Prognostic factors for early severe pulmonary complications 
after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:223-
229. 
23 De
vine SM, Geller RB, Lin LB et al. The outcome of unrelated donor bone marrow 
transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low 
dose methotrexate for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 
1997;3:25-33. 
24 Cutle
r C, Antin JH. Omission of day+[ADDRESS_646598] disease. 
Biol Blood Marrow Transplant. 2002;8:85 [Abstract]. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
I-4   
                                                                                                                                                                  
25 K
irken RA, Wang YL. Molecular actions of sirolimus: sirolimus and mTor. Transplant Proc. 
2003;35:S227-S230. 
26 Hackstein 
H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropi[INVESTIGATOR_501796]-mediated endocytosis by [CONTACT_167666]-derived dendritic cells. Blood. 
2002;100:1084-1087. 
27 Mon
ti P, Mercalli A, Leone BE et al. Rapamycin impairs antigen uptake of human dendritic 
cells. Transplantation. 2003;75:137-145. 
[ADDRESS_646599]
ein H, Taner T, Zahorchak AF et al. Rapamycin inhibits IL-4--induced dendritic cell 
maturation in vitro and dendritic cell mobilization and function in vivo. Blood. 2003;101:4457-4463. 
29 Ch
iang PH, Wang L, Liang Y et al. Inhibition of IL-12 signaling Stat4/IFN-gamma pathway 
by [CONTACT_501827] [correction of dendritc] cell function. 
Transplant Proc. 2002;34:1394-1395. 
30 Wo
ltman AM, de Fijter JW, Kamerling SW et al. Rapamycin induces apoptosis in monocyte- 
and CD34-derived dendritic cells but not in monocytes and macrophages. Blood. 
2001;98:174-180. 
31 Wo
ltman AM, van der Kooij SW, Coffer PJ et al. Rapamycin specifically interferes with GM-
CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 
expression. Blood. 2003;101:1439-1445. 
32 Ma
cDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a 
sirolimus/cyclosporine regimen for prevention of acute rejection in recipi[INVESTIGATOR_501797]. Transplantation. 2001;71:271-280. 
33 v
an Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L. A prospective 
randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant 
recipi[INVESTIGATOR_840]. Transplantation. 2003;75:1934-1939. 
34 Fl
echner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor 
drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 
2002;74:1070-1076. 
[ADDRESS_646600]. 2003;9:1079-1085. 
[ADDRESS_646601]. 2003;9:126-129. 
37 Co
tterell AH, Fisher RA, King AL et al. Calcineurin inhibitor-induced chronic nephrotoxicity 
in liver transplant patients is reversible using rapamycin as the primary immunosuppressive 
agent. Clin Transplant. 2002;[ADDRESS_646602] 7:49-51. 
38 M
cAlister VC, Gao Z, Peltekian K et al. Sirolimus-tacrolimus combination 
immunosuppression. Lancet. 2000;355:376-377. 
BM
T CLINICAL TRIALS NETWORK  GVHD Prophylaxis – Protocol 0402 
  Version 4.0 dated December 3, 2010 
 
 
I-5   
                                                                                                                                                                  
39 Ko
enen H, Michielsen E, Verstappen J, Fasse E, Joosten I. Superior T-cell suppression by 
[CONTACT_501828]506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-
lymphocyte induction, impaired memory responses, and persistent apoptosis. Transplantation. 
2003;75:1581-1590. 
40 Cianci
o G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus and 
sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and 
sirolimus in renal transplantation. I. Drug interactions and rejection at one year. 
Transplantation. 2004;77:244-251. 
41 Cianci
o G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus/sirolimus 
versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal 
transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation. 
2004;77:252-258. 
42 Be
nito AI, Furlong T, Martin PJ et al. Sirolimus (rapamycin) for the treatment of steroid-
refractory acute graft-versus-host disease. Transplantation. 2001;72:1924-1929. 
[ADDRESS_646603] disease. Biol Blood Marrow Transplant. 2002;8:87[abstract]. 
44 Co
uriel D, Hicks K, Saliba R et al. Sirolimus (rapamycin) for treatment of steroid-refractory 
chronic graft versus host disease. Biol Blood Marrow Transplant. 2003;9:67[abstract]. 
[ADDRESS_646604] disease prophylaxis in mismatched related donor or unrelated donor 
transplantation. Blood. 2003;102:1601-1605. 
[ADDRESS_646605] Disease Prophylaxis after Matched, Related Donor Peripheral Blood Stem Cell 
Transplantation. Biol Blood Marrow Transplant. 2004; 10:328-336. 